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ABSTRACT 
Immunosignaturing is a technology that allows the humoral immune 
response to be observed through the binding of antibodies to random sequence 
peptides. The immunosignaturing microarray is based on complex mixtures of 
antibodies binding to arrays of random sequence peptides in a multiplexed 
fashion. There are computational and statistical challenges to the analysis of 
immunosignaturing data. The overall aim of my dissertation is to develop novel 
computational and statistical methods for immunosignaturing data to access its 
potential for diagnostics and drug discovery.  
Firstly, I discovered that a classification algorithm Naive Bayes which 
leverages the biological independence of the probes on our array in such a way as 
to gather more information outperforms other classification algorithms due to 
speed and accuracy.  
Secondly, using this classifier, I then tested the specificity and sensitivity 
of immunosignaturing platform for its ability to resolve four different diseases 
(pancreatic cancer, pancreatitis, type 2 diabetes and panIN) that target the same 
organ (pancreas). These diseases were separated with >90% specificity from 
controls and from each other.  
Thirdly, I observed that the immunosignature of type 2 diabetes and cardio 
vascular complications are unique, consistent, and reproducible and can be 
separated by 100% accuracy from controls. But when these two complications 
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arise in the same person, the resultant immunosignature is quite different in that of 
individuals with only one disease.  
I developed a method to trace back from informative random peptides in 
disease signatures to the potential antigen(s). Hence, I built a decipher system to 
trace random peptides in type 1 diabetes immunosignature to known antigens. 
Immunosignaturing, unlike the ELISA, has the ability to not only detect the 
presence of response but also absence of response during a disease. I observed, 
not only higher but also lower peptides intensities can be mapped to antigens in 
type 1 diabetes. 
To study immunosignaturing potential for population diagnostics, I 
studied effect of age, gender and geographical location on immunosignaturing 
data. For its potential to be a health monitoring technology, I proposed a single 
metric Coefficient of Variation that has shown potential to change significantly 
when a person enters a disease state.  
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CHAPTER 1 INTRODUCTION 
Out of the many economic problems that we are facing today, health care 
expenditure is clearly the one that draws the most attention. When compared to 
total US energy spending, total US health care spending is clearly higher and 
brings more impact on the both social and financial life of the people. Figure 1-1 
shows the total U.S energy spending (Administration 2009) versus total U.S. 
health care spending (US Department of Health and Human Services 2010) 
 
 
Figure 1-1 U.S Energy Vs. Healthcare Spending from 1970-2004 
With more than 2.5 trillion dollars spent this financial year, the US health 
care expenditures continue to rise at a faster rate. With the current rate of increase 
in the expenditure, the total U.S spending would reach to 4 trillion dollars in 2015 
(US Department of Health and Human Services 2010).  Figure 1-2 shows the 
total U.S Healthcare expenditure projections.  
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Figure 1-2 Total U.S. Healthcare expenditures projections ($dollars) 
 The current scenario of post symptomatic medicine is based on treating a 
subject with a disease after diagnosis. With more than 2.5 trillion dollar 
expenditure, 88% of the cost of post symptomatic medicine goes into patient care 
ie taking care of sick people. 10% of the total expenditure goes into drug 
development and only 2% goes into diagnostics (US Department of Health and 
Human Services 2010). The primary reason for the expensive health care is often 
late diagnosis which means current drugs have to encounter a biological system 
which is already out of order. A paradigm shift is required to revolutionize health 
care which should be based on pre-symptomatic diagnosis rather than the current 
scenario of post symptomatic diagnosis. Towards the goal of an effective 
diagnostic, biological molecules are continuously being sought for their potential 
to be biomarkers for diseases.      
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1.1 BIOMARKERS 
In theory, a given biomarker molecule can serve as a proxy for detecting 
and diagnosing disease and hence could be the most effective means of measuring 
drug efficacy and improving patient health (Weston and Hood 2004). One of the 
most ubiquitous technologies used for biomarker identification is mass 
spectrometry (Li et al. 2005; L. Ackermann, E. Hale, and L. Duffin 2006). It has 
been widely used to search for diagnostic markers, and the high sensitivity has 
made it useful for identifying informative biomarker molecules that associate with 
disease. This process of reducing biomarkers down to a single or few best 
candidates occasionally leads to overtraining, where highly precise biomarkers 
that work well in small cohorts become harder to correlate with large and diverse 
test populations (Kiehntopf, Siegmund, and Deufel 2007). It is becoming 
increasingly apparent that utilizing higher numbers of biomarkers simultaneously 
can relieve some of this ‘low-feature-number’ classification problem. 
Unfortunately, some attempts at using mass spectrometry to identify disease-
associated mass spectrogram signatures have lead to skepticism about this concept 
(Chapman 2002). One of the major drawbacks of serum based biomarkers is 
dilution. The ability to detect small concentration has been tested and numerous 
issues with reproducibility and sensitivity have arisen (Barbosa et al. 2005; 
Diamandis and van der Merwe 2005). Were there a candidate biomarker that was 
abundant, unaffected by age, sex, race, or genetic factors, different between 
healthy and sick persons and physically stable, the problem would become 
simpler. One such candidate is the immunoglobulin molecule.    
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1.2     ANTIBODIES AS BIOMARKERS  
The immune system periodically monitors and performs surveillance 
against any foreign antigen or abnormal self activity. Although, invasive antigen 
concentration might be low during the early course of infection or disease, a B-
cell has the potential to effectively recognize the antigen by producing antibodies 
and rapidly clonally expanding leading to amplified signal.  At a given time point, 
an individual’s antibody repertoire consists of nearly 1010 different antibodies. 
The antibodies which are near to germline antibody clones are low affinity while 
with matured clones are of high affinity (Dotan et al. 2006). Taken together, this 
repertoire effectively determines an individual’s immunological status. This status 
is an indicative measure of individual immunization history or exposure to 
inflammation, infection or a chronic disease. Being exposed to any of the above 
changes, ones immunological status can be reflected by the rich information 
content present by different antibody profiles. Such rich information if deciphered 
could potentially be used for disease diagnostics even pre-symptomatically, 
vaccine evaluation and drug discovery.  
Preventive medicine relies on pre-symptomatic, high specificity detection 
of a disease. Towards this goal, there has been a spur to develop novel and 
efficient biomarkers of diseases that can be captured at an early onset for effective 
diagnosis and treatment. Although more than 100,000 biomarkers have been 
reported currently in the literature (Kurian et al. 2009) but only 43 are FDA 
approved (Amur et al. 2008). Clearly, novel technologies are required to improve 
current early biomarker discovery methods. But there is a significant challenge 
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involved in identifying biomarkers at early stages. One of the challenges involves 
the blood dilution problem. At an early stage of disease, concentrations of 
potential biomarker molecules are low which poses a clear identification problem 
for technologies. To overcome this limitation, one of the best ways out is to 
amplify the response of the biomarker. An individual immunological status at any 
given time point can be represented by its antibody profile. Also, antibodies can 
solve blood dilution problem. Abnormalities in immune system at early stage, 
activates B cells which can produce 5,000 to 20,000 antibodies/min (Cenci and 
Sitia 2007). Moreover the cell itself replicates every 70 hour (Cooperman et al. 
2004) with lifespan up to 100 days (Forster and Rajewsky 1990) which leads to ~ 
1011 amplification of signals from an antigen in a week. Antibodies are very stable 
allowing ease of sample processing, and convenience of using historically 
archived serum samples (Geijersstam et al. 1998) and also through saliva at 
extreme temperatures (Chase, Johnston, and Legutki 2012)  
Towards the goal of using antibodies as effective biomarkers, the primary 
concern is to know if antibodies are generated in diseases other than general 
inflammation, infection or vaccination particularly at an early stage. Literature 
review clearly suggests that the humoral immunity actively participates 
specifically and early in autoimmunity like T1D (Bonifacio et al. 2000; Imagawa 
et al. 2000) and arthritis (Schellekens et al. 2000; Thurlings et al. 2006). In T1D 
autoantibodies against Insulin, IA-2 and GAD-65 are used as promising clinical 
biomarkers for early diagnostics. Taken together, the presence of three 
autoantibodies can predict up to 75% risk of having T1D (Hawa et al. 2000). 
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Antibody response are also being observed in cardiovascular disease, Alzheimer’s 
disease and even different types of cancer (Ada and Jones 1986; Brichory et al. 
2001; Brydak and Machala 2000; Cox et al. 1994; DiFronzo et al. 2002; Hooks et 
al. 1979; Lennon, Lindstrom, and Seybold 1976; Sreekumar et al. 2004; Stockert 
et al. 1998; Wilder 1995; Restrepo et al. 2011) . Also, these antibodies have been 
observed to be present at long before the disease symptoms start to show up.     
1.3 ANTIBODY PROFILING TECHNOLOGIES 
Use of antibodies as biomarker shows both potential and promise to 
identify disease at an early stage. Given ~1010 antibodies that an individual has, 
clearly there is a requirement for a high throughput technology which could 
profile such a huge amount of information. Modern technologies are being 
developed, focusing on maximizing targets that antibodies can recognize with 
significant differential affinity. Current technologies have to maintain a balance in 
performance among various key factors (Bacarese-Hamilton, Gray, and Crisanti 
2003; Anderson and LaBaer 2005). The summary of some existing technologies 
to profile antibodies are given below.   
1.3.1 PROTEIN BASED ASSAYS 
These assays are primarily focused to span maximum coverage of antigen 
tested. In these assays, protein are either directly spotted on the surface or 
prepared in-vitro on the surface in a form of protein microarray. Whole protein 
arrays, on one hand have the capability to detect antibodies raised against 
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conformational epitopes but rely on appropriate folding mechanism for spotted 
protein.    
1. Spotted Protein Arrays: These assays consist of recombinant protein library 
selected as candidates by dissecting entire proteome via sequencing a 
pathogen of interest or selected immunogenic proteins from large proteome 
pathogens  (Bacarese-Hamilton, Gray, and Crisanti 2003; Fang, Frutos, and 
Lahiri 2002; Mattoon et al. 2005). Complete human proteomes could also be 
spotted for autoantibody screening against autoimmunity (Robinson et al. 
2002). The limitations of these technologies are they require prior knowledge 
of antigens and inefficient to probe membrane proteins.  
2. Nucleic Acid Programmable Protein Arrays (NAPPA): It is a promising 
technology which spots DNA encoding protein as probes while transcription-
translation happens dynamically on the surface. One of the advantages of such 
technology is the formation of protein dynamically on the surface which 
preserves the structure of the protein and also enables membrane protein to be 
spotted more efficiently than traditional assays (Anderson and LaBaer 2005; 
Ramachandran et al. 2008). The main limitation is lack of efficient discovery 
since it requires prior knowledge of antigens tested. It is technically 
demanding and has not become generally useful.  
3. Cell Lysate Arrays: This type protein array is a high throughput method to 
discover protein abundance or its modification state. These have wide 
dynamic range and multiplexed detection to quantify and compare multiple 
targets (Sheehan et al. 2005; Hall, Ptacek, and Snyder 2007). It consists of 
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complex samples such as tissue lysates that are spotted on the array and are 
exposed to antibodies. The main limitation lies in lack of reproducibility and 
identification of reactive antigen due to multiplexing.  
4. ELISA: It is one of the standard clinical assays to detect antibodies, the main 
limitation is that this assay is not high throughput and requires large amount 
of sera. This assay requires a prior knowledge of antigen and is not effective 
for antigen discovery.  
5. Luminex Assays: These assays require fewer amounts of sera compared to 
ELISA. Here, proteins are coupled to color coded beads, and using secondary 
labeled antibody binding is detected. This technology is high throughput and 
enables multiplexing due to wide availability of color coded beads, through 
which  a number of antigens can be measured in parallel (Burbelo, Ching et al. 
2010). The main limitation of these assays lies in tedious set up, expensive 
machinery and large amount of antigen.  
6. Luciferase Immunoprecipitation (LIPS): It is one of the solution phase 
immunoprecipitation assays that do not require use of radiolabeled antigen 
unlike traditional immunoprecipitation assays (Burbelo, Bren et al. 2007; 
Burbelo, Ching et al. 2007). This assay has greater performance measures and 
have been widely use to detect autoantibodies to autoimmune diseases 
especially herpes simplex virus (Burbelo et al. 2009) .The main limitation of 
this assay is to generate recombinant proteins with a luciferase tag which 
makes it more feasible for small proteomes. This assay might not be effective 
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for large scale screening but will be more useful when high specificity and 
sensitivity is required.  
1.3.2 PEPTIDE BASED ASSAYS 
This is one of the indirect approaches compared to protein based assays to 
detect target antibodies through their cross reactivities.  Overlapping peptide for a 
proteome assays may increase the performance while reducing the labor and the 
cost that is involved in direct protein spotting based technologies. Several reports 
suggest that small peptides have the potential to mimic linear and conformational 
mimotopes (Legutki et al. 2010). Antibodies have been known to bind the exact 
sequence on the antigen (epitope) and also bind to sequence similar to the original 
sequence (mimitope). Hence spotting peptides on a surface have been widely used 
to profile antibodies from a system. Some of the approaches are as follows  
1) Phage Display: It is one of the prominent methods to detect epitopes or 
mimotopes of antibody targets using cDNA fragments or random sequence 
peptides library respectively. Through this technology, many novel peptides 
sequences have been discovered that are cross reactive with a particular 
antibody (Derda et al. 2011; Meloen, Puijk, and Slootstra 2000). This 
technology typically consists of equivalent number of peptides sequences to 
total number of antibodies ~1010. The main limitation of this technology lies 
in the effort that requires multiple rounds of planning, isolation and finally 
sequencing of phage display.  
2) Epitope Peptide Array:  Pathogen specific peptide microarrays have been 
widely used for epitope recognition patterns (Reineke 2009). For a small 
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proteome, whole proteome sequence can be dissected into small overlapping 
peptides and for large proteomes, certain portion of bioinformatically or 
clinical predicted epitopes can be spotted  (Bialek, Swistowski, and Frank 
2003). These peptides have a potential for immuno diagnostic application or 
epitope discovery (Uttamchandani and Yao 2008).  
3) Random Peptide Microarray: It is based on using random peptides as 
mimotopes by constructing libraries. These can provide a quick and 
simultaneous measure of antibody binders and discovering diagnostic 
biosignatures specific to disease or vaccination. One such approach is 
immunosignaturing which utilizes random sequence peptide microarray to 
profile the humoral immune response (Boltz et al. 2009; Legutki et al. 2010; 
Halperin, Stafford, and Johnston 2011; Restrepo et al. 2011).  
1.4 IMMUNOSIGNATURING       
The Center for Innovations in Medicine at Biodesign Institute has 
developed a mimotopes-based immuno-diagnostic technology known as 
immunosignaturing. It combines the high throughput potential of random phage 
display libraries with the speed of the microarray. Antibody profiles generated 
during infection, chronic disease or vaccination can be uniquely captured by this 
technology, and which is informative for disease classification. The random 
peptide microarray consists of 10k, 20 residue peptides of random amino acid 
sequences, with a C-terminal linker of Gly-Ser-Cys-COOH. 19 of the amino acids 
(except cysteine) were selected by custom software completely at random at each 
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of the first 17 positions followed by a constant GSC as the C-terminus linker 
(Legutki et al. 2010). Each slide is first treated with amino-silane and activated 
with sulfo-SMCC, this produces a maleimide activated surface designed to react 
with the cysteine terminal peptides.  Each peptide is spotted in duplicate and 
fluorescent fiducials are applied asymmetrically with Alexa dye labeled peptides 
for quality assurance. Serum or plasma are diluted 1:500 in incubation buffer (3% 
BSA, 1XPBS, 0.05% Tween 20) and applied to the array after which secondary 
IgG antibody is added at 1nM. At the final stage, tertiary fluorescent labeled 
antibody are applied which can be detected through a scanner producing a 
signature of an individual. A cartoon of the immunosignaturing is shown in 
Figure 1-3 
 
Figure 1-3 Schematic representation of how immunosignaturing works. 
Glass slide is preprocessed with amino silane, then peptides are spotted with 
the help of linker. Antibody profiles of are captured when sera/plasma/saliva 
IgG antibodies binding to these peptide 
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These arrays show promise in diagnostic applications for several diseases. 
Recently the physical characterization of the immunosignaturing technology 
demonstrated that how using of antibodies as biomarkers can solve a problem for 
early diagnosis  (Stafford et al. 2012).  The first proof of principle study on 
influenza showed that immunosignatures  are reproducible, stable over time and 
can discern mice with influenza infection and immunization (Legutki et al. 2010). 
It has also been demonstrated that these arrays captured the complexities of the 
humoral immune response (Stafford et al. 2011). One of the advantages of the 
immunosignature is that it relies on antibodies which are relatively stable and can 
be accessed through sera, plasma or even saliva and can be used in immuno 
diagnostic applications (Chase, Johnston, and Legutki 2012). The 
immunosignaturing technique has also been successfully applied to distinguish 
Alzheimers disease (Restrepo et al. 2011), pancreas disease including pancreatic 
cancer, pancreatitis, panIN and type 2 diabetes (Kukreja, Johnston, and Stafford 
2012) , brain cancer and several types of cancer (unpublished data). The 
immunosignaturing clearly outperforms when compared to other clinical 
approaches in processing large number of samples inexpensively. Average slide 
cost about 67$ to process compared to several thousand dollars other biomarker 
discovery methods. The immunosignaturing are now been done on a silicon 
surface with more than 300,000 feature on a surface. It is 30X increase in peptide 
coverage compared to our existing arrays. Clearly there is a lot of information that 
comes with this new technology and this poses a computational and statistical 
challenging in analyzing this novel microarray technology. Several algorithms 
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and statistical methods have been developed for microarray data analysis in the 
literature including the areas in image processing of features, normalization, data 
transformations, feature selection methods, classification, clustering and 
dimensional reduction methods for microarray data analysis. With respect to 
immunosignaturing microarrays, novel method of feature identification using 
segmentation have been developed for spot analysis (Yang, Stafford, and Kim 
2011) and identification of latent factors for diseases through immunosignaturing 
data from structural equation and mixture modeling (Brown et al. 2011). Clearly, 
there is lot of requirement of informatics and statistical analysis that needs to be 
done on this technology. The next section, reviews the current existing methods 
for data analysis for microarrays.  
1.5 CHALLENGES IN MICROARRAY DATA ANALYSIS 
Microarrays in general have been extremely useful for high throughput 
screening in variety of applications including sequencing (Schena et al. 1998), 
SNP detection (Wang et al. 1998) and also for purely computational purposes of 
DNA computing (Kari and Landweber 2000). With the information content that 
the modern microarray brings to the table, it also increases the demand of 
computational and statistical methods to harness this information.    
One of the advantages of microarrays is that they allow high throughput 
inspection of biological features simultaneously. But this brings a huge challenge 
in data analysis due to sources of variation at each level, quantification of each 
feature into a single number etc. Some of the main challenges include   
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1. Noise: Microarrays including immunosignaturing are noisy in nature 
irrespective of scrutiny in performing experiments. The random stochastic 
noise is introduced inevitably at almost every step (Schuchhardt et al. 
2000). This includes noise in preparation of probes of mRNA or peptides, 
surface chemistry, humidity, target volume, spotting methodology (pin 
type), slide to slide variation, hybridization parameters (time, temperature, 
incubation period), non specific background, artifacts of contamination, 
scanning, segmentation, and towards the end of process in quantification 
of spot signal. The main challenge arises when features across different 
conditions are compared to determine if a particular one (gene, peptide) 
are different due to condition or random noise. Noise is one of the 
inevitable features that microarrays have to deal with although replication 
and randomization help to determine the true cause of variation.  
2. Normalization: Systematic differences often occur in microarray data due 
to various sources of variation. These differences might be in overall 
intensity, or specific trends due to artifacts of secondary or tertiary dyes. 
Normalization is required at almost every type of microarray analysis to 
remove these differences but consensus of which specific normalization 
method to use has not been achieved concretely.  
3. Experimental Design: It is one of the critical steps that are often ignored 
during a microarray experiment. In order to get a true response of effect of 
input variable to the output variable, sensitivity analysis should be done to 
observe the true cause of the output variable. Complete random design, 
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randomized block design involving blocking factors might be one of the 
features for good experimental design.  
4. High feature problem: Microarrays being a high throughput technology, 
examines thousands of feature (genes, peptides) in parallel to determine 
differential pattern in two or more conditions. This can be challenge due in 
indentifying true real features among less relevant features. Overall error 
rate should be keep in mind by also taking into account multiple testing 
corrections methods to calculate overall alpha rate. Using multiple testing 
procedures, one can ensure to find only relevant differential features, else 
with 10,000 features one can expect few peptides by random chance. To 
make sure, features are not just selected by chance, further clustering 
analysis should be performed without using prior knowledge of classes.  
5. Level of significance: To obtain differential expression profiles of 
hundreds of features over fewer samples, traditional classical methods like 
chi square test may not be valid. Challenges arise in choosing appropriate 
statistical measures to discover expression patterns above a threshold error 
rate.  
6. Biological factors: Although microarray technology provides a plethora 
of information of expression profiles of genes or peptides that are 
expressed or bind in different conditions, but there are many biological 
factors that might mislead the interpretation of this data. For gene 
expression microarrays, expression of genes may not correspond to the 
amount which determines the phenotype. For peptides and protein 
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microarrays, conformation, folding and PTM are biological factors which 
affect the signal of expression profiles. Validation of the observed features 
by different assays and taking orthogonal measurements should be 
supplemented by microarray experiments.    
7. Quality Control: Data analysis at each step of the process is required in 
order to ensure quality of data that is generated through the microarray. 
Certain threshold metrics need to be used that are specific for each 
technology to discard or accept the microarray data depending upon 
interference of noise with the signals.           
There are so many ways that microarray data can be influenced, since at each 
step of the procedure is complicated (Fujita et al. 2006). Hence, a protocol and 
standardization are made for storing large amount of data and to make it 
accessible to users (Brazma 2009). Some of the standards developed for quality 
assurances of microarray are normalization methods, ontologies for annotation, 
MAGE: a data exchange format and MIAME: minimum information about a 
microarray for making inference.  
Microarrays are extremely helpful in answering the high throughput biological 
research hypothesis, but it is a long way from the formation of hypothesis to 
reaching the right inference. Figure 1-4 shows the layout for step by step 
procedures in microarray data analysis.  
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Figure 1-4: Step by Step layout for microarray data analysis 
 
1.6 DATA PRE-PROCESSING AND NORMALIZATION  
Data pre-processing and normalization are the most important step before 
any data analysis methods. Preprocessing basically extracts and transforms the 
data into more meaningful form. The most common method of pre-processing is 
log transform (Yang et al. 2002). It provides values that are more easily 
interpretable. Measuring absolute differences in the features among different 
conditions might lead to false inferences. Secondly, log transformation  makes the 
distribution symmetrical and close to normal distribution (Long et al. 2001), this 
eases the process of applying classical statistical methods which assumes the data 
distribution is  normal. Due to the noise associated with the microarray data, it is 
always advisable to do repeated measures of a sample and take an average of a 
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sample with its technical replicate. A sample with less than <0.7 Person 
correlation coefficient should be discarded based on our experience. Along with 
combining the samples with the technical replicate, extreme caution must be 
given to the outliers. Outliers might be a cause of bad mechanical problem or it 
can be the actual sample differences which may be very heterogeneous in the 
population. Hence outliers should be treated with extreme caution and should not 
be removed from the analysis without any prior knowledge of the cause of the 
outliers. The primary use of microarrays is to find differences among the 
conditions and extract the relevant differential features associated with the 
difference. Hence the primary requirement before the data analysis is to normalize 
the data to remove bias for personnel, experimental and technology variation. 
There have been many normalization methods reported in the literature which can 
be useful for various microarray technologies. Normalization per median, in 
which each slide/sample is normalized to its median, is most common in peptide 
microarrays. Other normalization such as normalization per feature (gene or 
peptide) is also useful when samples of different batches or time points are 
compared for the analysis. Hence it is extremely important to transform the data 
and normalize the data depending on the hypothesis and microarray technology 
before proceeding towards the data analysis methods.      
1.7 EXPERIMENTAL DESIGN  
Experimental design is the most crucial and often neglected area in 
microarray experiments. For good experimental data, it is important that the 
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experiments are carefully designed. An experiment should be well thought and 
designed to make purposeful changes to the input variables to observe reasons for 
changes in the output response (Montgomery 2009). Lack of designed 
experiments might lead to misleading inference about the data and hence it is very 
important to provide data that includes major source of variation. Data analysis is 
performed after the experiments are performed and hence data analyst and 
statisticians have often no or less control about the source of the data. In a well 
designed experiment, the key thing is to identify the factor which contributes to 
the noise. 
Some of the key guidelines for experimental design are as follows  
1. Research Hypothesis: Stating the experimental question in detail and 
with specification is extremely useful before designing the experiment 
efficiently. Doing a literature search on the similar research questions 
might give an idea about effective design and possible outcomes.  
2. Microarray Technology: It is extremely useful to make an appropriate 
choice of microarray technology that can address the research question 
specifications. Choosing between cDNA/oligo arrays, commercial/custom 
arrays, brand specific, which features to spot ( gene, real space peptides, 
random sequence peptides, proteins etc) can be difficult but extremely 
vital to address for the research question.  
3. Factors of interests: The primary vital task in microarray experiments is 
to identify major inputs or factors that affect the output of the experiment 
for example testing efficacy of drug on given subjects, finding differential 
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features (gene, peptides) among conditions of interests. At the same time, 
it is also important to identify nuisance factors that would adulterate the 
output of the experiment and hence necessary methods (replication, 
randomizations) can be performed to rectify the effect of nuisance factors.  
4. Threshold statistics: Once the research hypothesis is formed, one of the 
prime decisions is choose the optimal value of type 1 and type 2 errors. 
Depending on the specificity and sensitivity level required to make the 
inference, its useful to decide when to reject the true null hypothesis and 
vice versa. Balanced has to achieved between power (rejecting null 
hypothesis when it is false) and alpha rate (not rejecting null hypothesis 
when it is false). Typically in microarray experiments power is chosen to 
be >90% and alpha rate to be less than 5%.  
5. Data analysis: Recording the data accurately is as important as data 
analysis and effective tools, computational and statistical methods should 
be chosen to make right and meaningful inference of the research 
hypothesis.    
 
The basic principles involved in the experimental design are:  
1.7.1 REPLICATION  
It is one of the key methods to remove experimental error by doing 
performing a parameter analysis more than once. The prime purpose for doing the 
replication is to test whether the observed differences in the data are significant. 
Replication at various levels in the microarray experiments enable the data quality 
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and hence strengthen the inference drawn from the data. Typically in the 
microarray experiments, replication should be performed starting from spot level 
where every feature (gene or peptide) should be spotted randomly across the slide 
to remove any bias of location on the intensity of the spot. Also, replication 
should be performed at the chip/slide level where a single biological sample is run 
of multiple slides under the same condition to remove any slide bias. This is often 
referred as technical replicate and any sample with Pearson correlation of less 
than 0.8 to its technical replicate should be discarded. On the top of that, 
microarray experiments should also include biological replicates to remove 
individual bias and personal variation that may adulterate the inference. Pooling 
of sample is often recommended to remove any individual biases but it is 
sometimes criticized to dilute the actual signal coming from individual and hence 
pooling should be used with caution in microarray experiments.  
1.7.2 RANDOMIZATION   
It is a technique often used in microarray experiments to opt for random 
choices for factors that are not of interests. These factors are often referred as 
nuisance factors which might influence the outcome of a microarray experiment. 
Spotting features randomly across the slide allows removing any biases due to 
location, choosing slides and running the sample condition randomly allows 
removing biases of slide or environment. Randomization may be sometimes be 
difficult to incorporate at various levels but often recommended to draw 
meaningful inferences.  
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1.7.3 BLOCKING    
A block is a subset of homogenous experimental conditions that are 
created for keeping the nuisance factor constant and then allowing the factor of 
interest to vary (Montgomery 2009). It allows eliminating the variability due to 
differences in homogenous blocks, this block can be age, sex, geographical 
location, print run batch etc. Both the randomization and blocking aim to reduce 
the nuisance factors with the difference that blocking can only be applied for 
factors which are under control. If the nuisance factors are not under control, 
randomization is the only solution.  
1.8 FEATURES SELECTION IN MICROARRAYS 
Microarray data expression values are often compared to a fixed number 
or between two or more samples expression values. In order to make statistical 
significant inference of the differential pattern, various tests are performed. Some 
of the key statistical methods are as follows:   
1.8.1 ONE SAMPLE T-TEST  
It is performed when an observed expression values of a feature (gene or 
peptide) e.g. vector ā is compared to a known fixed value to see if the observed 
expressional value is significantly different from the fixed expression value c. 
The test statistics used here is student t-distribution, where X’ is average of vector 
ā, c is known fixed value, s is the standard deviation of vector ā and n is the 
number. of observations in vector ā 
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From this equation t-values are calculated and compared to a t-table with df = n -1 
to obtain the significance level (p value ) and the hypothesis of no of difference 
between expression values of feature of interest to a fixed value is rejected if the p 
value is <0.05. The basic assumption made here is vector ā values follow normal 
distribution (Schena et al. 1995).  
Paired testing 
It’s often of interest to find out which features change significantly when a 
sample is exposed to a certain condition like temperature, environment etc. These 
are known as simultaneous tests, before and after tests or matched tests. In this 
case, statistical test is required to test if there is a significant difference between a 
feature before and after the test. For such experiments, one sample t-test is 
performed where X’ is replaced with difference between the mean Xd’.   
1.8.2 CHI SQUARE TEST FOR EXPRESSION VARIANCE 
Often variance is calculated for expression values of feature of interest 
(gene, peptide) multiple times through different technology to access if one 
technology provides significantly more uniform distribution of a feature of 
interest. In this case, chi square test statistics is calculated by 
χ2 ൌ  
ሺn െ 1ሻsଶ
σଶ
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Here s is the standard deviation of the sample and σ is the standard deviation of 
the population, if test statistics is larger than the critical value, null hypothesis of 
no significant difference between the variance is concluded (Schena et al. 1995).  
1.8.3 TWO SAMPLE TEST FOR MEANS 
Microarray expression values of one or more feature(s) (gene or peptide) 
for two conditions (disease vs normal) are often compared to find if there is a 
significant difference between the mean of a feature in each condition. If the 
interest is in the higher /lower value of a feature in one condition then one tail/two 
tail test is performed respectively.  
The test statistics used here is student t-distribution where X1’ and X2’ 
represent the average of a feature in condition 1 and 2 respectively. The term s1 
and s2 denotes the standard deviation of a feature in condition 1 and 2 
respectively. The term u1 and u2 represent the expected mean under the null 
hypothesis for condition 1 and 2 respectively. If the variance of a feature is not 
significantly different in two conditions, sp2 (pooled variance is used)  or else 
separate variances are used for t-statistics calculation, n1 and n2 denotes the 
sample size for condition 1 and 2 respectively.  
For equal variance  
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If the t-statistic is higher than the critical value at a defined significant level (95%) 
with degree of freedom v = n1+ n2 - 2 then the null hypothesis of mean of feature 
is equal in condition 1 and 2 is rejected (Schena et al. 1995).  
For unequal variance 
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If the t-statistic is higher than the critical value at a defined significant level (95%) 
with the degree of freedom υ, then the null hypothesis of equality of the mean of 
the feature in 2 conditions is rejected.  
1.8.4 ONE WAY ANOVA 
A feature of interest is often compared in multiple conditions to test if 
there is a significant difference among the means of a feature. For this, F-test or 1-
way ANOVA is used. The basic assumption of this model is that k samples are 
independent and all the populations are same variance with normal distribution. 
There are two sources of variation when the multiple groups are involved. SS 
(treat) is variation due to difference in the means of the groups and SS (error) is 
variation due to random variation. The mean square MS (treat) and MS (error) is 
calculated for the test statistics to find out if these variations are significantly 
different by taking the ratio of sum of squares to the degree of freedom. The 
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degree of freedom for treatment group is r-1, where r is the number of groups and 
for error is n-r where n is total number of samples. The F test basically tests if the 
MS (treat) is significantly higher than MS (error). If the obtained F value is then 
higher than the critical value of F (1-α, r-1, n-r), then the null hypothesis of 
equality of the means in different conditions is rejected and we conclude that 
there is a significant among the means of a feature of interest in multiple 
conditions.  
1.8.5 TWO WAY ANOVA    
1-way ANOVA methods investigate data which is influenced by only one 
factor. Often a feature (peptide or gene) might be affected by two factors which 
may or may be not independent. For such a study, 2-way ANOVA is performed. 
The overall goal for such a study is to see if the mean of a feature is different in 
treatment A conditions and also in treatment B conditions. Such analysis is often 
complicated if there is interaction between treatment A and treatment B. Hence a 
test for interaction is performed where the mean square due to interactions is 
compared to mean square error and if F value obtained is greater than the critical 
value then we conclude that there is a significant interaction between the two 
treatments. If there is no significant interaction between the two treatments, then 
individual F-tests are performed for effect of factor A and factor B separately on a 
particular feature of interest. This is done by taking ratio of mean square for MS 
(treat A) and MS (error) and also ratio of MS (treat B) and MS (error) to calculate 
F statistics specific to the hypothesis for treatment A and treatment B 
respectively.  
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1.8.6 MULTIPLE COMPARISONS 
Typically in microarray experiments, large numbers of features are 
simultaneously tested for significance in various conditions. In that case there is 
always a chance of an inflated overall alpha level. For each feature tested against 
the alpha level, the overall probability to obtain false positives increases. For 
example, if each feature (gene or peptide) is tested against 5% type 1 error level, 
and simultaneously 10,000 features are tested, the overall probability of type 1 
error increases significantly. To maintain the overall probability of type 1 error as 
5%, several corrections are suggested including Bonferroni, Benjamini and 
Hochberg false discovery rates (Hochberg and Benjamini 1990).   
1.9 DATA ANALYSIS METHODS IN MICROARRAYS 
Once the optimal number of differential features is selected after choosing the 
appropriate feature selection method and correction of multiple testing, data 
becomes ready for analysis. With the few selected features for different 
conditions, various analysis and visualization tools have been developed. Some of 
the key visualization tools are  
1. Box plots: It graphically represents several descriptive statistics of a given 
data sample. It gives the visual representation of a particular sample or class 
25th, 50th (median) and 75th percentiles along with outlier points.  
2.  Histogram: It is a graph showing frequency distribution of values with 
horizontal axis showing the range of values and vertical axis showing the 
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distribution. This representation is useful to determine the distribution of data 
(normal, left/right skewed, bimodal, uniform etc).  
3. Scatter plot : It is the simplest tool to represent two classes on horizontal and 
vertical classes respectively. This graph is useful to visualize how feature 
intensity differs in two conditions and thus a range of features can be selected 
from scatter plot fulfilling certain conditions ( 2X, >2X fold etc)  
4. Line graph: It is useful in time series analysis or comparing certain features 
of interest over different samples. It gives a visual representation of trajectory 
of features over selected samples.  
1.9.1 CLASSIFICATION METHODS FOR MICROARRAYS 
Once the optimal number of differential features is selected by the feature 
selection method, a classifier is needed to build a model that can classify different 
classes of interests based on the features selected. Once a model is built on the 
training data, this model is tested for its performance against the test data. Model 
performance can be calculated by various metrics including accuracy, sensitivity, 
specificity and area under ROC curve. There have been algorithms described in 
the literature specific for different types of microarray data.  A more complete 
review is presented in chapter 3. Linear discriminant analysis is one of the 
traditional methods for studying gene expression data. But certain technologies 
like protein arrays and peptide arrays have a different mechanism of binding of 
targets to the probe due to which traditional methods may not work effectively. 
Due to this reason, a classifier should be chosen with caution with respect to the 
microarray technology involved.  
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1.9.2 CLUSTERING METHODS FOR MICROARRAYS   
Clustering analysis is the most frequently used multivariate technique to 
analyze different types of microarrays. This technique is most appropriate when 
no prior knowledge regarding the data is known or unsupervised learning is 
required. In recent years the clustering analysis of biological data in unsupervised 
setting has caught the attention of many researchers that has resulted to use 
clustering analysis to analyze their microarray data (Yeh et al. 2009; Jupiter and 
VanBuren 2008). Clustering aims to group certain objects based on a similarity 
measure called distance. The distance between two n-dimensional vectors is 
calculated by a distance metric. Some of the frequent distance metrics are 
Euclidean, Manhattan, Chebchev, Correlation, Mahalannobis and Minkowski 
distance (de la Fuente, Brazhnik, and Mendes 2002). Prior to using a distance 
metrics, it is extremely important to normalize (per slide or per feature) and 
transform (z-transform or log transform) the data to remove any experimental 
bias. The important question before the clustering methods is choice of various 
distance measures mentioned above. Every distance metrics have their own 
limitations and advantages; hence it is extremely vital to examine the 
characteristics of feature (gene or peptide) and samples. Some of the rule of 
thumbs involves using Euclidean and Manhattan metrics when the clustering 
features are different while the clustering samples are same. For the opposite case, 
correlation distance metrics is more appropriate. There are many clustering 
methods developed and used for microarray expression data. One of the simplest 
and most commonly used methods is k-means clustering which require prior 
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knowledge of the number of clusters (k) (Spadone et al. 2012; Yu et al. 2012). 
The algorithm randomly chooses k points as centers and in every iteration, 
updates the centers based on inter and intra clusters distances. Towards the end of 
the iterations, k clusters are formed. This method is quite robust, but is vulnerable 
to the initial selection of k points and the number of iterations. Hence these two 
parameters should be varied to obtain a stable set of k clusters. This method is 
often used to cluster samples based on their microarray expression signatures. 
Apart from clustering samples into separate clusters, hierarchical clustering is 
considered to be more appropriate for microarray expression data (Eisen et al. 
1998; Heyer, Kruglyak, and Yooseph 1999). Here, a dendrogram is constructed 
based on a distance metrics between either samples or features (gene or peptide) 
or even both. One classical representation of hierarchical clustering in microarray 
expression data is heat map. Here, samples and features are clustered 
hierarchically in x axis and y axis respectively and the spot intensity for the 
corresponding feature and sample are represented as gradient of colors where red 
color denotes high binding, yellow is average binding and blue as low binding. 
Heat maps help to visualize the binding of selected features over samples in the 
experiment. It gives the picture of how samples are clustered together in axis as a 
tree and how features are clustered together in y axis.  
1.9.3 DIMENSIONAL REDUCTION PROCEDURES        
One of the challenges in the microarray experiments is the large number of 
dimensions. Every experiment has at least 10 samples in each class, and every 
sample is run for 10,000 features (genes or peptides) or more. This leads to the 
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data explosion for microarrays. For each sample having 10,000 data points or 
more, it becomes a challenge to visualize. A natural approach is to try to reduce 
the number of dimensions by eliminating the irrelevant dimensions. A common 
approach in this regard is constructing fewer dimensions that account for most 
variation in the data. This is the approach used by Principal Component 
Analysis (PCA).  It basically works by calculating a new system of dimension or 
coordinates, which are in linear combination of all the other variables in such a 
way to incorporate maximum variance. The direction of the coordinates are 
eigenvectors of the covariance matrix of the patterns. The eigenvalue with the 
largest absolute value will signify maximum variation along its eigenvector. The 
projections of the data points in the new dimensional systems are called the 
principal components of the data. By projecting the n-dimensional input vector 
into a space of 2 or 3 dimensions, dimensional reduction is achieved. Apart from 
its usefulness, it has some serious limitations of only relying on the first order 
statistical characteristics (variance) of the data (Eisen et al. 1998; Hilsenbeck et al. 
1999). Another approach in the dimensional reduction procedure is Independent 
Component Analysis (ICA) (Bell and Sejnowski 1995), which considers higher 
order statistical dependencies (kurtosis, skewness) for separating a multivariate 
microarray data into additive subcomponents assuming the mutual statistical 
independence. The prime difference between the two approaches is that in PCA, 
the directions of the new axes are perpendicular to each other, while in ICA the 
new axes are not necessarily perpendicular to each other. ICA has been found to 
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be more effective for solving blind source separation and has the potential to 
separate the multiplexed signals from individual features (genes or peptides).     
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CHAPTER 2 COMPARATIVE STUDY OF CLASSIFICATION 
ALGORITHMS FOR IMMUNOSIGNATURING DATA 
2.1 ABSTRACT 
High-throughput technologies such as DNA, RNA, protein, antibody and 
peptide microarrays are often used to examine differences across drug treatments, 
diseases, transgenic animals, and others.  Typically one trains a classification 
system by gathering large amounts of probe-level data, selecting informative 
features, and classifies test samples using a small number of features.  As new 
microarrays are invented, classification systems that worked well for other array 
types may not be ideal.  Expression microarrays, the most prevalent array type, 
have been used for years to help develop classification algorithms.  Many 
biological assumptions are built into classifiers that were designed for these types 
of data.  One of the more problematic is the assumption of independence, both at 
the probe level and again at the biological level.  Probes for RNA transcripts are 
designed to bind single transcripts.  At the biological level, many genes have 
dependencies across transcriptional pathways where co-regulation of 
transcriptional units may make many genes appear as being completely 
dependent.  Thus, algorithms that perform well for gene expression data may not 
be suitable when other technologies with different binding characteristics exist.  
The immunosignaturing microarray is based on complex mixtures of antibodies 
binding to arrays of random sequence peptides.  It relies on many-to-many 
binding of antibodies to the random sequence peptides.  Each peptide can bind 
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multiple antibodies and each antibody can bind multiple peptides.  This 
technology has been shown to be highly reproducible and appears promising for 
diagnosing a variety of disease states.  However, it is not clear what is the optimal 
classification algorithm for analyzing this new type of data.  
We characterized several classification algorithms to analyze 
immunosignaturing data.  We selected several datasets that range from easy to 
difficult to classify, from simple monoclonal binding to complex binding patterns 
in asthma patients.  We then classified the biological samples using 17 different 
classification algorithms. 
Using a wide variety of assessment criteria, we found the ‘Naïve Bayes’ 
far more useful than other widely used methods due to its simplicity, robustness, 
speed and accuracy. 
 The ‘Naïve Bayes’ algorithm appears to accommodate the complex 
patterns hidden within multilayered immunosignaturing microarray data due to its 
fundamental mathematical properties. 
2.2 INTRODUCTION  
Serological diagnostics have received increasing scrutiny recently (Haab 
2003; Whiteaker et al. 2007) due to their potential to measure antibodies rather 
than low-abundance biomarker molecules.  Antibodies avoid the biomarker 
dilution problem and are recruited rapidly following infection, chronic, or 
autoimmune episodes, or exposure to cancer cells.  Serological diagnostics using 
antibodies have the potential to reduce medical costs and may be one of the few 
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methods that allow for true pre-symptomatic detection of disease.  For this reason, 
our group has pursued immunosignaturing for its ability to detect the diseases 
early and with a low false positive rate.  The platform consists of a peptide 
microarray with either 10,000 or 330,000 peptides per assay.  This microarray is 
available for standard mathematical analysis, but for a variety of reasons, certain 
methods of classification enable the best accuracy (Reimer, Reineke, and 
Schneider-Mergener 2002) (Merbl et al. 2009).  Classification methods differ in 
their ability to handle high or low numbers of features, the feature selection 
method, and the features’ combined contribution to a linear, polynomial, or 
complex discrimination threshold. Expression microarrays are quite ubiquitous 
and relevant to many biological studies, and have been used often when studying 
classification methods.  However, immunosignaturing microarrays may require 
that we change our underlying assumptions as we determine the suitability of a 
particular classifier. 
In order to establish the question of classification suitability, we examine a 
basic classification algorithm, Linear Discriminant Analysis (LDA).  LDA is 
widely used in analyzing biomedical data in order to classify two or more disease 
classes (Braga-Neto and Dougherty 2004) (Stemke-Hale et al. 2005) (Sima et al. 
2005) (Braga-Neto and Dougherty 2004).  One of the most commonly used high-
throughput analytical methods is the gene expression microarray. Probes on an 
expression microarray are designed to bind to a single transcript, splice variant or 
methylation variant of that transcript.  These one-on-one interactions provide 
relative transcript numbers and cumulatively help to define high-level biological 
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pathways.  LDA uses these data to define biologically relevant classes based on 
the contribution of differentially expressed genes.  This method often uses 
statistically identified features (gene transcripts) that are different from one 
condition to another.  LDA can leverage coordinated gene expression to make 
predictions based on a fundamental biological process.  The advantage of this 
method is that relatively few features are required to make sweeping predictions.  
When features change sporadically or asynchronously, the discriminator 
predictions are adversely affected.  This causes low sensitivity in exchange for 
occasionally higher discrimination.  Tree-based methods use far more features to 
obtain a less biased but less sensitive view of the data.  These methods can 
partition effects even if the effect sizes vary considerably.  This approach can be 
more useful than frequentist approaches where it is important to maintain 
partitions in discreet groups. 
Immunosignaturing has its foundations in both phage display and peptide 
microarrays.  Most phage display methods that use random-sequence libraries 
also use fairly short peptides, on the order of 8-11 amino acids (Cwirla et al. 
1990). Epitope microarrays use peptides in the same size range, but typically far 
fewer total peptides, on the order of hundreds to thousands (Nahtman et al. 2007).  
Each of these methods assumes that a single antibody binds to a single peptide, 
which is either detected by selection (phage display) or by fluorescent secondary 
antibody (epitope microarray).  Immunosignaturing uses long 20-mer random-
sequence peptides that have potentially 7 or more possible linear epitopes per 
peptide.  Although immunosignaturing must make do with only 10,000 to 
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~300,000 peptides, the information content derived from partial binding makes 
these data useful in ways quite different from phage display (Boltz et al. 2009) 
(Brown et al. 2011) (Halperin, Stafford, and Johnston 2011) (Legutki et al. 2010) 
(Restrepo et al. 2011).  
 
Figure 2-1 One-to-one correspondence found in gene expression microarrays 
is not observed for the immunosignaturing arrays. 
The complexity in analysis arises from the many-to-many relationship 
between peptide and antibody Figure 2-1.  This relationship imposes a particular 
challenge for classification because a simple one-to-one relationship between 
probe and target, idiomatic for gene expression microarrays, allows a coherent 
contribution of many genes that behave coordinately based on biological stimuli.  
That idiom is broken for immunosignaturing microarrays, where each peptide 
may bind a number of different antibodies and every antibody might bind a 
number of peptides.  Unless disease-specific antibodies find similar groups of 
peptides across individuals, very little useful information is available to the 
classifier.  The aim of this work is to assess the performance of various 
classification algorithms on immunosignaturing data. 
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We have considered 17 diverse data mining classification methods.  For 
feature selection, we used a simple t-test when we examined two classes, and a 
fixed-effects 1-way ANOVA for multiple classes with no post-hoc stratification.  
We have assessed these algorithms’ ability to handle increasing numbers of 
features by providing four different sets of peptides with increasing p-value 
cutoff.  The four levels include from 10 (minimum) to >1000 (maximum) 
peptides.  Each algorithm is thus tested under conditions that highlight either 
synergistic or antagonistic effects as the feature numbers increase. 
 
2.3 MATERIALS AND METHODS 
2.3.1 TECHNOLOGY 
A peptide microarray described previously (Boltz et al. 2009) (Brown et 
al. 2011) (Halperin, Stafford, and Johnston 2011) (Legutki et al. 2010) (Restrepo 
et al. 2011) was used to provide data for analysis.  Two different sets of 10,000 
random peptide sequences are tested.  The two peptide sets are non-overlapping 
and are known as CIM10Kv1 and CIM10Kv2.   
2.3.2 SAMPLE PROCESSING 
Samples consist of sera, plasma or saliva – each produces a suitable 
distribution of signals upon detection with an anti-human secondary IgG-specific 
antibody.  Samples are added to the microarray at 1:500 dilutions in sample buffer 
(1xPBS, 0.5% Tween20, 0.5% Bovine Serum Albumin (Sigma, St. Louis, MO)), 
IgG antibodies are detected through a biotinylated secondary anti human IgG 
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antibody (Novus anti-human IgG (H+ L), Littleton, CO), which binds the primary 
antibody.  Fluorescently labeled streptavidin is used to label the secondary 
antibodies and the slide is scanned with an Agilent ‘C’ laser scanner in single-
color mode. 16-bit images are processed using GenePix Pro 8, which provides the 
tabular information for each peptide in a continuous value ranging from 0-65,000.  
Four unique data sets have been used in this analysis, 2 run on the CIM10Kv1 and 
2 on the CIM10Kv2.  Each individual sample was run in duplicate; replicates with 
>0.8 Pearson correlation coefficient were considered for analysis.  
2.3.3 DATASETS 
Center for Innovations in Medicine, Biodesign Institute, Arizona State 
University has an existing IRB 0912004625, which allows analysis of blinded 
samples from collaborators. 
a.) T1D data set: This dataset contains 80 sera samples (41 controls and 39 T1D 
children ages 6 to 13). These samples were tested on the CIM10kV1microarrays. 
b.) Alzheimer’s disease data set: This dataset contains 23 samples (12 controls 
and 11 Alzheimer’s disease subjects).  These were tested on the CIM10kV2 
microarrays. 
c.) Antibodies dataset:  This dataset contains 50 samples and has 5 groups of 
monoclonal antibodies, arbitrarily arranged.  All monoclonal were raised in 
mouse, and use the same secondary detection antibody.  Samples were run on the 
CIM10kV1 microarrays. 
d.) Asthma dataset: This dataset consists of 47 unique samples containing serum 
from patients in 4 distinct classes corresponding to the household environment.  
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Condition A consists of 12 control subjects who had no environmental stimuli.  
Condition B consists of 12 subjects who had stimuli but no asthma-related 
symptoms.  Condition C consists of 11 subjects who had no stimuli but with 
clinical asthma.  Condition D consists of 12 subjects who have both stimuli and 
clinical asthma.  Samples were tested on the CIM V2 10K microarrays.  Asthma 
datasets were been analyzed by considering all four conditions using ANOVA in 
order to study the combined effect of stimuli and asthma on subjects and then by 
considering pair wise comparison of condition A vs. B, A vs. C, and B vs. D. 
2.3.4 DATA PREPROCESSING, NORMALIZATION AND FEATURE 
SELECTION 
The 16-bit tiff images from the scanned microarrays were imported into 
GenePix Pro 6.0 (Molecular Devices, Santa Clara, CA).  Raw tabular data were 
imported into Agilent’s GeneSpring 7.3.1 (Agilent, Santa Clara, CA).  Data were 
median normalized per array and log10 transformed.  For feature selection we used 
Welch-corrected T-test with multiple tested (FWER=5%).  For multiple groups 
(Antibody and Asthma datasets) we used 1-way fixed-effects ANOVA. 
2.3.5 DATA MINING CLASSIFICATION ALGORITHMS 
Four distinct peptide features are chosen for the comparison study.  For 
each analysis, peptides are selected by t-test or ANOVA across biological classes, 
with 4 different p-value cutoffs.  Cutoffs were selected to obtain roughly 
equivalent sized feature sets to assess the ability of each algorithm to process 
sparse to rich feature sets.  Once the significant features were collected, data was 
imported into WEKA (Hall et al. 2009) for classification.  The algorithms 
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themselves spanned a wide variety of classifiers including Bayesian, regression 
based methods, meta-analysis, clustering, and tree based approaches.   
We obtained accuracy from each analysis type using leave-one-out cross-
validation.  We obtained a list of t-test or ANOVA-selected peptides at each 
stringency level.  The highest stringency uses peptides with p-values in the range 
of 10-5 to 10-10 and contains the least ‘noise’.  The less-stringent second set uses p-
values approximately 10-fold higher than the most stringent.  The third contains 
the top 200 peptides and the forth contains ~1000 peptides at p<0.05.  Although 
different numbers of peptides are used for each dataset, each peptide set yields the 
same general ability to distinguish the cognate classes.  The WEKA default 
setting of parameters were used for every algorithm to avoid bias and over fitting.  
These default parameters are taken from the cited papers listed below for each 
algorithm.  Brief details of default parameters and algorithms are listed  
1. Naïve Bayes: Probabilistic classifier based on Bayes theorem.  Numeric 
estimator precision values are chosen based on analysis of the training 
data.  In the present study, normal distribution was used for numeric 
attributes rather than kernel estimator (John and Langley 1995). 
2. Bayes net: Probabilistic graphical model that represents random variables 
and conditional dependencies in the form of a directed acyclic graph.  A 
Simple Estimator algorithm has been used for finding conditional 
probability tables for Bayes net.  A K2 search algorithm was used to 
search network structure(Friedman, Geiger, and Goldszmidt 1997) (Yu 
and Chen 2005).  
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3. Logistic Regression (Logistic R.): A generalized linear model that uses 
logistic curve modeling to fit the probabilistic occurrence of an 
event(Friedman, Hastie, and Tibshirani 1998).  The Quasi-Newton method 
is used to search for optimization.  1x108 has been used for ridge values in 
the log likelihood calculation (Cessie and Houwelingen 1992).  
4. Simple Logistic: Classifier for building linear logistic regression models.  
For fitting the logistic model ‘LogitBoost’, simple regression functions are 
used.  Automatic attribute selection is obtained by cross validation of the 
optimal number of ‘LogitBoost’ iterations (Landwehr, Hall, and Frank 
2005).  Heuristic stop parameter is set at 50.  The number of maximum 
iterations for LogitBoost has been set to 500. 
5. Support Vector Machines (SVM): A non-probabilistic binary linear 
classifier that constructs one or more hyper planes to be can be used for 
classification.  For training support vector classes, John Platt’s sequential 
minimal optimization algorithm was used which replaces all missing 
values (Platt 1998). Here multiclass problems are used using pair-wise 
classification. The complexity parameter is set to 1. Epsilon for round off 
error is set to 1x10*-12. PolyKernel is the set to be kernel. The tolerance 
parameter is set to 0.001 (Hastie and Tibshirani 1998; Keerthi et al. 2001).   
6. Multilayer Perceptron (MLP): A supervised learning technique with a 
feed forward artificial neural network through back-propagation that can 
classify non-linearly separable data (Chaudhuri and Bhattacharya 2000; 
Gardner and Dorling 1998).  The learning rate is set to 0.3 and momentum 
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applied during updating weights is set to 0.2.  The validation threshold use 
to terminate the validation testing is set to 20. 
7. K nearest neighbors (KNN): Instance based learning or lazy learning 
which trains the classifier function locally by majority note of its 
neighboring data points.  Linear NN Search algorithm is used for search 
algorithm (Aha, Kibler, and Albert 1991; Weinberger, Blitzer, and Saul 
2006). K is set to 3. 
8. K Star: Instance based classifier that uses similarity function from the 
training set to classify test set.  Missing values are averaged by column 
entropy curves and global blending parameter is set to 20 (Cleary and 
Trigg 1995).  
9. Attribute Selected Classifier (ASC):  ‘Cfs subset’ evaluator is used 
during the attribute selection phase to reduce the dimension of training and 
test data.  The ‘BestFit’ search method is invoked after which J48 tree 
classifier is used (Hall 1998).  
10. Classification via clustering (K means):  Simple k means clustering 
method is used where k is set to the number of classes in the data set 
(Hartigan 1985).  Euclidean distance was used for evaluation with 500 
iterations. 
11. Classification via Regression (M5P): Regression is a method used to 
evaluate the relationship between dependent and independent variables 
through an empirically determined function.  The M5P base classifier is 
used which combines conventional decision tree with the possibility of 
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linear regression at the nodes.  The minimum number of instances per leaf 
node is set to 4 (Quinlan 1992).  
12. Linear Discriminant Analysis (LDA): Prevalent classification technique 
that identifies the combination of features that best characterizes classes 
through linear relationships.  Prior probabilities are set to uniform and the 
model as homoscedastic. 
13. Hyper Pipes: Simple, fast classifier that counts internally defined 
attributes for all samples and compares the number of instances of each 
attribute per sample.  Classification is based on simple counts.  Works 
well when there are many attributes (Ian H. Witten 2011). 
14. VFI:  Voting feature interval classifier is a simple heuristic attribute-
weighting scheme.  Intervals are constructed for numeric attributes.  For 
each feature per interval, class counts are recorded and classification is 
done by voting.  Higher weight is assigned to more confident intervals.  
The strength of the bias towards more confident features is set to 0 
(G¸venir and «akIr 2010). 
15. J48:  Java implementation of C4.5 algorithm.  Based on the Hunt’s 
algorithm, pruning takes place by replacing internal node with a leaf node.  
Top-down decision tree/voting algorithm (Salzberg 1994).  0.25 is used 
for the confidence factor.  No Laplace method for tree smoothing (Quinlan 
1996). 
16. Random Trees:  A tree is grown from data that has K randomly chosen 
attributes at each node.  It does not perform pruning.  K-value (log2 
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(number of attributes) + 1) is set at zero.  There is no depth restriction.  
The minimum total weight per leaf is set to 1 (Ian H. Witten 2011). 
17. Random Forest (R. Forest):  Like Random Tree, the algorithm constructs 
a forest of random trees (Breiman 2001) with locations of attributes 
chosen at random.  It uses an ensemble of unprune decision trees by a 
bootstrap sample using training data.  There is no restriction on the depth 
of the tree; number of tress used is 100. 
2.3.6 TIME PERFORMANCE 
CPU time was calculated for every algorithm at the four different 
significance levels.  This time was measured on a standard PC (Intel dual core, 
2.2 GHz 3 Gb RAM) that was completely dedicated to WEKA.  To measure CPU 
time, open source jar files from WEKA were imported to Eclipse where the 
function ‘time ()’ was invoked prior to running the classification including the 
time required for cross validation.  Most Windows 7 services were switched off; 
the times reported were an average of 5 different measurements. 
2.4 RESULTS 
2.4.1 OVERALL PERFORMANCE MEASURE OF CLASSIFICATION 
ALGORITHMS OVER ALL DATASETS 
For each dataset, accuracies are measured at four levels (top 10, 50,200, 1000 
peptides) at various levels of significance.  Overall average performance measure 
is calculated for each algorithm for a given data set.   
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Table 2-1 shows the overall average percentage score for each algorithm 
calculated by averaging accuracy, specificity, sensitivity and area under ROC 
curve under all levels of significance.  Scores >90% are marked in bold.  The 
MLP algorithm did not finish due to huge memory requirements on last level of 
significance and is averaged based on first three levels of significance.  For type 1 
diabetes, Alzheimer’s and antibodies dataset, >6 algorithms scored >90% average 
score.  Overall, Naïve Bayes had the highest average score (90.4%) and was 
always among top 3 algorithms among all datasets. 
2.4.2 PERFORMANCE MEASURE OF CLASSIFICATION 
ALGORITHMS AT DIFFERENT LEVELS OF SIGNIFICANCE OVER 
ALL DATA SETS 
For each data set, different levels of significance are chosen to measure 
the performance accuracy of each algorithm.  These levels contain approximately 
equal number of peptides for each data set.  The first level contains 10 peptides 
selected from the t-test (lowest p value) and hence contains the least noise.  Next, 
approximately 50 peptides, 200 peptides and 1000 peptides were chosen for the 
other three levels. Table 2:2-8 shows 4 different performance measures 
(accuracy, specificity, sensitivity and area under ROC curve) at different levels of 
significance over 7 datasets.   
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Table 2-1: Overall performance measures of classification algorithms on datasets. 
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Table 2-2 Performance measures of data mining algorithm at different levels of significance over T1D dataset 
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Table 2-3: Performance measures of data mining algorithm at different levels of significance over Alzheimer’s 
dataset 
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Table 2-4: Performance measures of data mining algorithm at different levels of significance over Antibodies 
dataset 
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Table 2-5: Performance measures of data mining algorithm at different levels of significance over Asthma 
dataset 4 classes. 
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Table 2-6: Performance measures of data mining algorithm at different levels of significance on A & B 
conditions 
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Table 2-7: Performance measures of data mining algorithm at different levels of significance on A & C 
conditions 
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Table 2-8: Performance measures of data mining algorithm at different levels of significance on B & D 
conditions 
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For the Asthma dataset, we considered all conditions A-D together, then 
performed the pair-wise comparisons of condition A and B, condition A and C, 
and condition B and D at three different levels of significance.  Measures >90% 
are marked in bold.  For the diabetes dataset, 9 algorithms achieved >90% score.  
For Alzheimer’s and the Antibodies dataset, 6 algorithms achieved >90% score.  
Naïve Bayes scored 100% in all 4 measures at the first level of significance in the 
Alzheimer’s dataset and scored 91.5% average score on the Antibodies dataset.  
For the Asthma datasets, the highest score was <80%.  Only Naïve Bayes had 
>90% specificity for more than one level of significance.  For two conditions in 
Asthma datasets, Naïve Bayes and VFI scored >90% average score. Acc: 
Accuracy, Sp: Specificity, Sn: Sensitivity, AUC: Area under ROC curve, Avg: 
Average score in % for each algorithms, dnf: “Did Not Finish”, * denotes Avg. 
from 3 significance levels. Measures >90% are marked in bold.  
 
2.4.3 COMPARATIVE ANALYSIS OF WORST TIME PERFORMANCE 
OF CLASSIFICATION ALGORITHMS OVER DATA SETS 
The amount of time taken by each algorithm to build the model and 
perform cross validation was measured.   
Table 2-9 shows the time in milliseconds for each algorithm at the lowest 
level of significance when the number of peptides nears 1000.  Random Tree was 
the fastest, at ~1000 milliseconds (average) to complete the task, while MLP was 
the worst which did not finish due to high memory requirements.  Random tree, 
Hyper Pipes, Naïve Bayes, VFI and KNN were the five fastest algorithms; each 
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took less than ~4000 milliseconds to complete classification of >1,000 peptides.  
Logistic Regression and Attribute Selected Classifier, MLP were among the 
slowest algorithms taking more than 20 minutes to perform classification of 
>1,000 peptides.  The absolute ranking for every algorithm was consistent per 
dataset; only three datasets have been considered to measure time performance. 
Random Tree, KNN, Hyper Pipes and VFI were among the fastest. MLP were 
among the slowest with dnf: “Did not finish”. Time measurements less than 10 
seconds are marked in bold. 
 
Table 2-9: Worst case time performance (in ms) of classification algorithms 
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2.4.4 COMPARATIVE ANALYSIS OF TIME PERFORMANCE OF 
CLASSIFICATION ALGORITHMS AT DIFFERENT LEVELS OF 
SIGNIFICANCE OVER THREE DATA SETS 
For each level of significance, time was measured for each algorithm to 
build the model and for cross validation.  At the highest level of significance ( 
about 10 peptides ), each algorithm was fast enough to complete the task in under 
25 seconds.  Execution times increased as the level of significance was lowered 
due to the higher number of features and increased difficulty in constructing the 
model.   
Table 2-10 shows classification algorithms time performance at various 
levels of significance. 
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Table 2-10: Time performance (in ms) of classification algorithms on datasets 
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2.4.5 RESULTS SUMMARY 
We have explored several disparate classifiers using a relatively new type of 
microarray data: immunosignaturing data.  The tested algorithms come from a 
broad family of approaches to classify data.  We chose algorithms from Bayesian, 
regression, trees, multivariate and meta analysis and we believe we have sampled 
sufficiently that the results are relevant.  From  
Table 2-1 we found that Naïve Bayes had a higher average performance 
than all other algorithms tested.  Naïve Bayes achieved > 90% average for 2 
classes datasets where there is a clear distinction between two classes.  For the 
multi-class the Antibodies dataset, where there is a clear difference between 
different types of antibodies, Naïve Bayes scored 88% average accuracy and was 
ranked third, close to the 93.3 % accuracy of random forest.  On the asthma 
dataset, containing four classes, none of the algorithms were able to achieve more 
than 75% accuracy.  This matches the biological interpretation very well.  Naïve 
Bayes outperformed all algorithms for speed and accuracy, achieving 77.7% 
average score overall.  Naïve Bayes was one of the top five fastest algorithms, 
~500 times faster than the logistic regression.  A summary of the all algorithms 
performance measures and time is given in below and described in Table 2-11.  
Distance metrics have been defined to access performance measures for all 
algorithms compared to the highest scoring algorithm on a given dataset. #Rank 1, 
Rank 2: No. of times algorithm ranked 1st and 2nd on 7 datasets, #>90%: No. of 
times algorithm scored overall average score >90% on 7 datasets, Distance: 
magnitude an algorithm trails behind on average from the Rank 1 for the datasets 
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(5% or less distance are marked in bold). Time: performance slower with 
respective to fastest algorithm. Time performances slower by 5 folds to fastest 
algorithm are marked in bold.     
Table 2-11: Summary of performance and time measures of classification 
algorithms 
 
Summary of all classification algorithms are given below  
1. Naïve Bayes: Naïve Bayes performed best overall with > 90% overall 
average score.  It was always among the top 3 algorithms in all 7 
comparisons.  It ranked first 5 out 7 times when comparing all datasets.  It 
was on an average just 0.3% behind the rank 1 algorithm in overall 
comparison.  It is 2X slower than the fastest algorithm due to its 
mathematical properties.  It would be feasible to perform large-scale 
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classification studies using Naïve Bayes. 
2. Multilayer Perceptron (MLP): It ranked second with overall score of 
87.3% and was very close to SVM.  The overall score is biased since MLP 
did not finish for levels containing ~1000 peptides and hence scored was 
averaged from just the three levels.  It was the slowest algorithm and 
infeasible to perform large-scale classification. 
3. Support Vector Machines (SVM): Although it ranked third, it was not 
significantly different from the MLP in terms of performance measures.  It 
was 700X faster than MLP and achieved >90% measured accuracy 3 
times.  Both MLP and SVM were <5% behind the rank 1 algorithm on 
average. 
4. VFI: VFI ranked fourth in overall performance measures and was the 
among top 5 fastest algorithms due to its voting method.  Four times it 
obtained >90% average overall accuracy and ranked 2nd twice. 
5. Hyper Pipes: Hyper pipes ranked fifth overall in performance measures 
and was among the fastest of the tested algorithms, likely due to its 
inherently simplistic ranking method.  It was <8% from first place 6 times. 
6. Random Forest: Random forest ranked sixth in overall performance 
measures and performed better on datasets having multiple classes 
(Antibodies and Asthma).  It was 21 times slower than the fastest 
algorithm due to bootstrapping. 
7. Bayes net: Ranked in the middle for overall accuracy and time.  It scored 
>90% overall measures twice.  It was slower than the Naïve Bayes due to 
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construction of networks in the form of an acyclic graph and it is relatively 
inefficient compared to Naïve Bayes due to the change in network 
topology during assessment of probability. 
8. K means: K-means ranked eighth in overall performance measures and 
was 34X slower than the fastest algorithm in time performance due to the 
multiple iterations required to form clusters.  It performed far better for 2 
classes compared to multiple classes because guaranteed convergence, 
scalability and linear separation boundaries are more easily maintained. 
9. Logistic Regression: Logistic regression ranked ninth in overall accuracy.  
It was >90% three times.  It was among the worst in time performance, 
being ~1000 times slower than the fastest algorithm as it needs to regress 
on high number of features.  It is efficient for small numbers of features 
and sample sizes > 400. 
10. Simple Logistic: It ranked tenth in overall performance measures and 
ranked first on the diabetes dataset.  It ranked second in multiclass Asthma 
dataset.  It was slow in time performance due to LogitBoost iterations. 
11. K nearest neighbors: It performed well on the 2 classes dataset but did 
not perform as well for multi class datasets.  It was >90% performance for 
only rather difficult diabetes dataset.  This may be related to evenly 
defined but diffuse clusters related to the subtle differences between the 
asthma patients. 
12. K star: It performed >90% for only the diabetes dataset and was 9 times 
slower than the fastest algorithm.  This algorithm may also be sensitive to 
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the even and diffuse clusters described by this dataset. 
13. M5P: It did not perform well on either time performance or accuracy.  It 
never achieved >90% average score and was 22 times slower than the 
fastest algorithm due to formation of comprehensive linear model for 
every interior node of the unpruned tree. 
14. J48: Top 5 fastest algorithm due to rapid construction of trees.  It was 
>20% behind from the rank 1 algorithm on an average; its lower 
performance may possibly be due to formation of empty/insignificant 
branches which often leads to overtraining. 
15. Random Trees: It was the fastest algorithm since it builds trees of height 
log(k) where k is the number of attributes, however it achieves poor 
accuracy since it performs no pruning.  
16. Attribute Selected Classifier (ASC): One of the slowest algorithms as it 
had to evaluate attributes prior to classification. It underperformed in 
performance measures due to the C4.5 classifier limitations that prevent 
overtraining. 
17. Linear Discriminant Analysis (LDA): Its performance accuracy 
decreased as the number of features increased due to its inability to deal 
with highly variant data.  It was slow (>500X slower than the fastest 
algorithm) since it tries to optimize class distinctions but the variance 
covariance matrix increases dramatically as the number of features 
increased. 
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2.5 DISCUSSION 
The comparisons provided in this article provide a glimpse into how 
existing classification algorithms handle data with intrinsically different 
properties than traditional microarray expression data.  Immunosignaturing 
provides a means to quantify the dispersion of serum (or saliva) antibodies that 
result from disease or other immune challenge.  Unlike most phage display or 
other panning experiments, fewer but longer random-sequence peptides are used.  
Rather than converging to relatively few sequences, the immunosignaturing 
microarray provides data on the binding affinity of all 10,000 peptides with high 
precision.  Classifiers in the open-source program WEKA were used to determine 
whether any algorithm stood out as being particularly well suited for these data.  
The 17 classifiers, which were tested, are readily available and represent some of 
the most widely used classification methods in biology.  However, they also 
represent classifiers that are diverse at the most fundamental levels.  Tree 
methods, regression, and clustering are inherently different; the grouping methods 
are quite varied and top-down or bottom-up paradigms address data structures in 
substantially different ways.  Given this, we present and interpret the results from 
our tests, which we believe will be applicable to any dataset with target-probe 
interactions similar to immunosignaturing microarrays. 
From the comparisons above, Naïve Bayes was the superior analysis method in all 
aspects.  Naïve Bayes assumes a feature independent model, which may account 
for its superior performance.  It relies on the degree of correlation of the attributes 
in the dataset; for immunosignaturing, the number of attributes can be quite large.  
 65 
In gene expression data, where genes are connected by gene regulatory networks, 
there is a direct and significant correlation between hub genes and dependent 
genes.  This relationship affects the performance of Naïve Bayes by limiting its 
efficiency through multiple containers of similarly - connected features 
(Hedenfalk et al. 2001; Li, Zhang, and Ogihara 2004; Liu, Li, and Wong 2002). In 
peptide-antibody arrays, where the signals that arise from the peptides are 
multiplexed signals of many antibodies attaching to many peptides, there is no 
direct correlation between peptides, but there is a general trend.  Moreover, there 
is a competition of antibodies attaching to a single peptide, which makes it 
difficult for multiple mimotopes to show significant correlation with each other.  
Thus, the 10,000 random peptides have no direct relationships to each other each 
contributes partially to defining the disease state.  This makes the 
immunosignaturing technology a better fit for the assumption of strong feature 
independence employed by the Naïve Bayes technique, and the fact that 
reproducible data can be had at intensity values down to 1 standard deviation 
above background enables enormous numbers of informative, precise, and 
independent features.  Presence or absence of a few high- or low-binding peptides 
on the microarray will not impact the binding affinity for any other peptide, since 
the kinetics ensures that the antibody pool is not limiting.  This is important when 
building microarrays with >300,000 features per physical assay, as in our newest 
microarray.  More than 90% of the peptides on either microarray demonstrate 
normal distribution for binding signals.  This is important since feature selection 
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methods used in this analysis (t-test and one way ANOVA) and the Naïve Bayes 
classifier all assume normal distribution of features. 
The Naïve Bayes approach requires relatively little training data, which makes it a 
very good fit for the biomarker field.  The sample sizes usually range from N=20-
100 for the training set.  Naïve Bayes has other advantages as well: it can train 
well on a small but high feature data set and still yield good prediction accuracy 
on a large test set.  Any microarray with more than a few thousand probes 
succumbs to the issue of dimensionality.  Since Naïve Bayes independently 
estimates each distribution instead of calculating a covariance or correlation 
matrix, it escapes relatively unharmed from problems of dimensionality. 
The data used here for evaluating the algorithms were generated using an array 
with 10,000 different features, almost all of which contribute signal.  We have 
arrays with >300,000 peptides per assay (current microarrays are available from 
www.peptidearraycore.com) which should provide for less sharing between 
peptide and antibody, effectively spreading out antibodies over the peptides with 
more specificity.  This presumably will allow resolving antibody populations with 
finer detail.  This expansion may require a classification method that is robust to 
noise, irrelevant attributes and redundancy.  Naïve Bayes has an outstanding edge 
in this regard as it is robust to noisy data since such data points are averaged out 
when estimating conditional probabilities.  It can also handle missing values by 
ignoring them during model building and classification.  It is highly robust to 
irrelevant and redundant attributes because if Yi is irrelevant then P (Class|Yi) 
becomes uniformly distributed.  This is due to that fact that the class conditional 
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probability for Xi has no significant impact on the overall computation of 
posterior probability.  Naïve Bayes will arrive at a correct classification as long as 
the correct classes are even slightly more predictable than the alternative.  Here, 
class probabilities need not be estimated very well, which corresponds to the 
practical reality of immunosignaturing: signals are multiplexed due to 
competition, affinity, and other technological limitation of spotting, background 
and other biochemical effects that exist between antibody and mimotope. 
2.5.1 TIME EFFICIENCY 
As the immunosignaturing technology is increasingly used for large-scale 
experiments, it will result in an explosion of data.  We need an algorithm that is 
accurate and can process enormous amounts of data with low memory overhead 
and fast enough for model building and evaluation.  One aims for next-generation 
immunosignaturing microarrays is to monitor the health status of a large 
population on an on-going basis.  The number of selected attributes will no longer 
be limited in such a scenario.  For risk evaluation, complex patterns must be 
normalized against themselves at regular intervals.  This time analysis would 
require a conditional probabilistic argument along with the capacity of accurately 
predicting the risk with low computational cost.  The slope of Naïve Bayes on 
time performance scale is extremely small, allowing it to process a large number 
of attributes. 
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2.6 CONCLUSION 
Immunosignaturing is a novel approach which aims to detect complex 
patterns of antibodies produced in acute or chronic disease.  This complex pattern 
is obtained using random peptide microarrays where 10,000 random peptides are 
exposed to antibodies in sera/plasma/saliva.  Antibody binding to the peptides is 
not one-to-one but a more complicated and multiplexed process.  The quantity 
and appearance of this data appears numerically, distributionally, and statistically 
the same as gene expression microarray data, but is fundamentally quite different.  
The relationships between attributes and functionality of those attributes are not 
the same.  Hence, traditional classification algorithms used in gene expression 
data might be suboptimal for analyzing immunosignaturing results.  We 
investigated 17 different kinds of classification algorithm spanning Bayesian, 
regression, tree based approaches and meta-analysis and compared their leave-
one-out cross-validated accuracy values using various numbers of features.  We 
found that the Naïve Bayes classification algorithm outperforms the majority of 
the classification algorithms in classification accuracy and in time performance, 
which is not the case for expression microarrays (Stafford and Brun 2007).  We 
also discussed its assumptions, simplicity, and fitness for immunosignaturing 
data.  More than most, these data provide access to the information found in 
antibodies.  Deconvoluting this information was a barrier to using antibodies as 
biomarkers.  Pairing immunosignaturing with Naïve Bayes classification may 
open up the immune system to a more systematic analysis of disease. 
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CHAPTER 3 APPLICATION OF IMMUNOSIGNATURE TECHNOLOGY 
TO RESOLVE PROFILES OF CLOSELY RELATED PANCREAS 
DISEASES 
3.1 ABSTRACT 
Immunosignaturing is a technology that allows the humoral immune 
response to be observed through the binding of antibodies to random sequence 
peptides.  Profiles of the antibody repertoire produced during infection or during 
long-term chronic disease have proven to be informative for disease classification.  
An important unanswered question relative to this technology is whether different 
diseases that target the same organ and result in similar early phenotypes have 
similar or distinguishable immunosignatures.  This question is of clinical 
relevance when considering patients who present with similar symptoms early 
during their disease.  The pancreas is one such organ; disease that affects this 
organ can cause the patient both broad and acute distress, with little to distinguish 
the disease source.  If the cause were made clear without biopsy, and could be 
accomplished during routine monitoring, earlier intervention could improve 
health.  Pancreatic cancer, chronic or acute pancreatitis, diabetes mellitus, 
hepatitis B or C infection, and other diseases can deeply affect the function of the 
pancreas, complicating diagnosis.  We tested the immunosignaturing platform for 
its ability to resolve four different diseases that target the same organ; pancreatic 
cancer, pre-pancreatic cancer (panIN), type II diabetes and acute pancreatitis.  
These diseases were separated with >90% specificity from controls and from each 
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other.  We also describe a mathematical method that allows identification of 3 
distinct components of an immunosignature: disease specific, ‘housekeeping’ and 
patient specific variation.  The first component is useful in diagnosing disease, the 
second for baseline for the technology and third for monitoring changes in a 
healthy individual over time. 
Keywords: Immunosignature, immune profile, random peptide microarray, 
microarray proteomics, pancreas disease, pancreatic cancer, type II diabetes, 
panIN, pancreatitis 
3.2 INTRODUCTION  
In theory, a given biomarker molecule can serve as a proxy for detecting 
and diagnosing disease and could be the most effective means of measuring drug 
efficacy and improving patient health (Weston and Hood 2004).  One of the more 
ubiquitous technologies used for biomarker identification is mass spectrometry 
(L. Ackermann, E. Hale, and L. Duffin 2006; Lamont et al. 2006; Li et al. 2005).  
It has been widely used to search for diagnostics biomarkers, and the high 
sensitivity has made it useful for identifying informative biomarker molecules that 
associate with disease.  This process of reducing biomarkers down to a single or 
few best candidates occasionally leads to overtraining, where highly precise 
biomarkers that work well in small cohorts become harder to correlate with large 
and diverse test populations (Kiehntopf, Siegmund, and Deufel 2007).  It is 
becoming increasingly apparent that utilizing higher numbers of biomarkers 
simultaneously can relieve some of this ‘low-feature-number’ classification 
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problem.  Unfortunately, some attempts at using mass spectrometry to identify 
disease-associated mass spectrogram signatures have lead to skepticism about this 
concept (Chapman 2002; Davies 2000)  
One of the major drawbacks of serum-based biomarkers is the dilution in 
the blood volume.  The ability to detect small concentrations of protein or other 
biological compounds reproducibly has been tested and numerous issues with 
reproducibility and sensitivity have arisen (Barbosa et al. 2005; Diamandis and 
van der Merwe 2005; Elias et al. 2005).  Were there a candidate biomarker that 
was abundant, unaffected by age, sex, race, or genetic factors, different between 
healthy and sick persons and physically stable, the problem would become 
simpler.  One such candidate is immunoglobulin molecules.  Antibodies are 
amplified during an illness so dilution is less of a problem, they are differentially 
abundant between healthy and ill person, they are stable and are relatively 
unaffected by genetic factors.  The humoral immune response can distinguish 
non-self antigens, modified self-antigens in the case of autoimmune disease, and 
neo-antigens in the case of many cancers (Ada and Jones 1986; Brichory et al. 
2001; Brydak and Machala 2000; Cox et al. 1994; DiFronzo et al. 2002; Hooks et 
al. 1979; Lennon, Lindstrom, and Seybold 1976; Sreekumar et al. 2004; Stockert 
et al. 1998; Wilder 1995). 
In order to visualize changes in the antibody repertoire en masse, we 
developed a system we call ‘immunosignaturing’ (Boltz et al. 2009; Brown et al. 
2011; Halperin, Stafford, and Johnston 2011; Legutki et al. 2010; Restrepo et al. 
2011).  We capture and display the complexities of humoral immunity using a 
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microarray of random-sequence peptides.  The system works for any isotype and 
has detected autoimmune disease, cancer, infectious disease, and chronic disease.  
The microarray is commercially printed to reduce variability and cost; technical 
reproducibility between replicate arrays averages 0.95 but is often >0.99. 
While we have seen clear distinctions between disease and healthy controls, we 
had not tested the idea that immunosignatures might be quite similar if a general 
inflammation response is raised for a particular target organ, though the primary 
disease might be quite different.  We tested four different diseases that each 
affects the pancreas, leading to similar acute symptoms, but leading to 
substantially different late-stage symptoms (Dugernier et al. 2003; Fineberg et al. 
2005; Orchekowski et al. 2005).  Clinically, this would aid patients who present 
with similar early symptoms.  If the immunosignatures revealed distinctions 
regardless of the common symptoms, it would enhance early intervention and 
could improve patient health.  Is a general inflammation response driving the 
early humoral immune response in pancreatic disease or are antibody profiles 
distinct enough to predict disease.  We examined patients with pancreatic cancer, 
pancreatitis, a pre-pancreatic cancer condition known as panIN, and type II 
diabetes. 
Pancreatic cancer refers to a malignant neoplasm of the pancreas.  About 
95% of pancreatic tumors arise within the exocrine component of pancreas 
(Hruban et al. 2001; Li et al. 2004).  Pancreatitis is inflammation of the pancreas 
due to ectopic or restricted activation of enzymes (Saluja and Steer 1999).  PanIN 
stands for Pancreatic Intraepithelial Neoplasia and is the initial stage of pancreatic 
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cancer (Hruban et al. 2000), also considered a non-carcinomic dysplasia.  Type II 
diabetes is a chronic condition in which body has insulin resistance and deficiency 
resulting in high glucose level in the body (Katsilambros et al. 2006).  There has 
been no complete survey of pancreatic diseases in the context of humoral 
immunity, but there is increasing evidence that patients with one pancreas disease 
have higher risk of a subsequent pancreas disease due to shared pathology and 
immunological involvement including autoimmunity (Ekbom et al. 1994; Huxley 
et al. 2005; Lowenfels et al. 1993; Deshpande et al. 2005; Inoue et al. 2006; 
Okazaki and Chiba 2002)  
An immunosignature is the cumulative information from selected random-
sequence peptides that bind differentially to antibodies from healthy controls vs. 
disease patients.  Peptides are selected using statistical measures (t-test or 
ANOVA).  Each signature, whether at a single time point from multiple patients 
with the same disease or from a single patient across multiple time points, can be 
considered a vector.  This vector has three major components: 1) the disease 
component, 2) the unchanged component and 3) the personal variation 
component.  Figure 3-1 (A) illustrates the three components, (B) explains the 
three components over the array. The (3,4) array is laid out in order to explain the 
three components.  The block in red explains the personal variation component 
since all peptides in the array have different binding. The block in black (2, 1), (2, 
2), (3, 1), (3, 2) explains the disease component (uniqueness).  These peptides are 
different in disease groups vs. controls.  The third component (normal 
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component) is explained in the blue block (4, 1), (4, 2) and also whole of 3rd 
column peptides which is consistent in the all the groups.  
 
Figure 3-1: (A) shows Immunosignaturing vector comprising of three major 
components. (B) explains these components in (3*4) array. Red block 
showing the personal variation component, black block showing the disease 
component while the blue block showing the normal 
 
The first component consists of peptides that show a relative ‘up’ or 
‘down’ response during the course of disease compared to healthy controls.  A 
simple t-test with multiple testing corrections applied can identify peptides that 
are reproducibly higher or lower in patients vs. controls.  Typically, biomarkers 
are missing in healthy controls and begin to appear in patients with a given 
disease.  In immunosignaturing, signals can be either higher or lower between 
disease and control; this is not typical for the biomarker paradigm. 
The second component represents peptides that do not change between 
disease and healthy individuals.  These antibodies are not activated during 
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disease, and may simply be circulating or basal level antibodies produced against 
a common infection or vaccination.  This component helps quantify the part of the 
immunosignature that does vary during the course of disease, helping to establish 
a baseline of variance and dynamic range. 
The third component is personal variation and signifies the behavior of an 
individual’s own immune system.  This component is necessary when 
establishing a baseline for a patient over time.  These three components are 
extracted mathematically from a given immunosignature.  We present these three 
components in the context of our analysis of four pancreas diseases. 
3.3 MATERIALS AND METHODS 
3.3.1 MICROARRAY 
The CIM 10K array is a 2-up microarray containing 10,000 random-
sequence 20-mer peptides attached via a maleimide reaction to the NH3 terminal 
sulfur of cysteine, creating a covalent attachment (Boltz et al. 2009; Brown et al. 
2011; Halperin, Stafford, and Johnston 2011; Legutki et al. 2010; Restrepo et al. 
2011).  The CIM 10K microarray is available to the public at 
www.peptidemicroarraycore.com.  
3.3.2 SAMPLES PROCESSING 
Plasma samples from patients and healthy controls were stored at -80OC 
until needed.  Samples were aliquoted and refrozen at -20OC.  Samples were 
diluted at 1:500 in sample buffer (1xPBS, 0.5% Tween20, 0.5% Bovine Serum 
Albumin (Sigma, St. Louis, MO)) and exposed to the array according to the 
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protocol in (Legutki et al. 2010).  Antibodies were detected with 5nm Alexafluor 
647-labeled streptavidin (Invitrogen, Carlsbad, CA), which bound 5nM 
biotinylated anti-human secondary antibody (Novus anti-human IgG (H+ L), 
Littleton, CO).  Microarrays were scanned and converted to tabular data as in 
(Legutki et al. 2010).  Median foreground signal was used as the value which 
best-represented binding of antibody to peptide. 
3.3.3 SAMPLES 
Center for Innovations in Medicine, Biodesign Institute, Arizona State 
University has an existing IRB 0912004625, which allows analysis of blinded 
samples from collaborators. 
1) Type II diabetes: 17 plasma samples which had poorly controlled type II 
diabetes with no history of CHF (Congestive Heart Failure) and MF (Myocardial 
Infraction). 
2) Pancreatic cancer: This set contains 13 plasma samples from patients with 
ductal adenocarcinoma of the pancreas. 
3) Pancreatitis: This set contains 10 plasma samples of patients with refractory 
pancreatitis. 
4) PanIN: This set contains 5 plasma samples.  Samples were obtained from a 
single family with history of pancreatic cancer.  Samples were diagnosed with a 
pre-stage of pancreatic cancer. 
5) Common Controls:  This set contain 16 plasma samples from the diabetes 
study. 
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3.3.4 DATA ANALYSIS 
The raw tabular data were imported to GeneSpring 7.3.1 (Agilent, Santa 
Clara, CA).  Data were median normalized per array and log10 transformed.  
Feature selection used t-test with family-wise Multiple Error correction of 5% 
(FWER=5%).  For multiple groups we used 1-way fixed-effects ANOVA, 
FWER=5%. All p-values presented are after FWER correction.  The three 
components were selected as follows:  component 1 (disease component) was 
selected by using t-test.  Component 2 (unchanged component) was selected by 
ANOVA (FWER = 5%) on all samples including controls and disease, these 
peptides are the ones which were not selected by ANOVA signifying no 
significant change over samples excluding those peptides that were selected for 
component 1.  Component 3 (unchanged component) are those peptides that 
passed ANOVA (FWER= 5%) on all samples including disease and controls. For 
classification, Naïve Bayes and leave one out cross-validation were used.  
Classification was performed in open source JAVA software WEKA (Hall et al. 
2009).  
3.4 RESULTS 
3.4.1 ANALYSIS OF IMMUNOSIGNATURING VECTORS 
10 samples of pancreatitis (Kijanka et al.), 5 samples of panIN (PN), 17 
samples of type II diabetes (T2D), 13 samples of pancreatic cancer (Kijanka et 
al.) and 16 samples of healthy controls were run in duplicate on the 10K peptide 
microarrays.  Technical replicates with Pearson’s correlation coefficient <0.90 
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were discarded.  For each disease, the three components listed in Table 3-1 were 
determined as a number of peptides at a given p-value (p<0.05, FWER= 5%).   
Features that comprise each of the three immunosignaturing components 
were identified at an adjusted p<0.05 and are presented in Table 3-1.  The disease 
components of pancreatic cancer and panIN contribute from 10-20% (lowest to 
highest) to the net immunosignaturing vector, while the disease component of 
type II diabetes and pancreatitis contributes little (< 3%) to the net vector.  The 
unchanged components within type II diabetes, pancreatitis and panIN contribute 
17-23% (average=19%) to the net vector while that of pancreatic cancer 
contributes <5%.  The personal variation component comprises most of the 
immunosignaturing net vector in pancreatic cancer, with 60-80% (average=76%).  
 
Table 3-1: Distribution of three components for pancreas disease: 
# peptides Type 2 
diabetes 
Pancreatic 
cancer 
Pancreatitis PanIN 
Disease component 92  1058 258 1696 
Unchanged 
component 
1700 536 2235 2041 
Personal variation  8208 8406 7507 6263 
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3.4.2 IMMUNOSIGNATURING OF EACH PANCREAS RELATED 
DISEASE VS COMMON CONTROLS  
Each of the diseases tested were subjected to a test/training analysis 
consisting of feature selection (component 1) followed by classification using 
Naïve Bayes and leave-one-out cross-validation.  Naïve Bayes treats features as 
completely independent sources of information, which has advantages for a 
system like immunosignaturing, less so for expression or SNP microarrays where 
there is a biological connection across features.  
We did a Welsh t-test between each pancreas disease and common control with 
multiple testing corrections and the null hypothesis was for 92 peptides with 
p<5e-2 for type 2 diabetes, 244 peptides with p<5e-3 for pancreatic cancer, 258 
peptides with p<5e-2 for pancreatitis and 233 peptides with p<5e-4 for panIN.  
 
3.4.3 IMMUNOSIGNATURING OF TYPE II DIABETES AND 
CONTROLS  
For type 2 diabetes, Figure 3-2 shows the most informative peptides 
among the 90 selected features that were upregulated in the tested disease state.  
The principal component analysis shows that ~70% of the variance is explained 
by the first two components.   
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Figure 3-2 Heatmap and PCA analysis of 90 peptides for type II diabetes and 
controls 
  
The performance from the peptides that compose the disease immunosignaturing 
component is shown in Table 3-2, where specificity > 93%.  
Table 3-2 Performance measure and classification table of type II diabetes 
and controls 
 
3.4.4 IMMUNOSIGNATURING OF PANCREATIC CANCER AND 
CONTROLS  
For pancreatic cancer, the heatmaps in Figure 3-3 show that 
approximately half of the informative peptides in the 244 show high binding 
response and other half shows low binding response. In principal component 
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analysis, about 65 % of variance is explained. The two groups are well-separated 
by these two components. More than 90% performance measures were obtained 
for this set.   
 
 
Figure 3-3: Heatmap and PCA analysis of pancreatic cancer and controls 
The performance from the peptides that compose the disease immunosignaturing 
component is shown in Table 3-3, where specificity > 93%.  
Table 3-3: Performance measure and classification table of pancreatic cancer 
and controls 
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3.4.5 IMMUNOSIGNATURING OF PANCREATITIS AND CONTROLS  
For pancreatitis, about 25% of the top 262 peptides showed high binding 
response while the rest showed lower binding response.  For the principal 
component analysis, 60% of the variance is explained by the first two components 
and the two groups are well separated.  The performance accuracy is >95% with 
100% specificity. 
 
Figure 3-4: Heatmap and PCA analysis of pancreatitis and controls 
The performance from the peptides that compose the disease immunosignaturing 
component is shown in Table 3-4, where specificity is 100%.  
Table 3-4: Performance measure and classification table of pancreatitis and 
controls 
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3.4.6 IMMUNOSIGNATURING OF PANIN AND CONTROLS  
For panIN, the heatmap shows that much of the top 233 peptides showed 
lower binding response while some showed higher binding response. In principal 
component analysis about 70% of the variance is explained by two components 
and the groups are very well separated. The performance accuracy is more than 
95% with 100% specificity 
 
 
Figure 3-5: Heatmap and PCA analysis of panIN and controls 
The performance from the peptides that compose the disease immunosignaturing 
component is shown in Table 3-5, where specificity is 100%.  
 
 85 
Table 3-5: Performance measure and classification table of panIN and 
controls 
 
We established the primary features that distinguish disease vs. control, 
along with the p-value cutoff, classification accuracy, specificity and sensitivity 
using Naïve Bayes error and leave one out cross validation.  We then asked of the 
peptides that are changed between control and each disease, how many are up or 
down compared to controls. Of note, detecting informative signals less than 
normal is a feature not easily done for ELISA-type assays.  For type II diabetes, 
most (~90%) of the peptides intensities were high compared to controls while for 
panIN, the same percentage were lower.  For pancreatic cancer and pancreatitis, 
between 50 and 60 % were lower compared to controls while 40 to 50% of the 
selected peptides were higher.  Given the initial question of similarity between 
diseases that affect the same target organ, and how much of an immunosignature 
is derived from a general inflammation response, we asked how many of these 
peptides were in common, and how well could we distinguish the diseases from 
each other. 
 
3.4.7 IMMUNOSIGNATURING OF PANCREAS DISEASE WITH EACH 
OTHER 
Features that distinguish each disease from every other were identified 
using corrected t-test and presented in Table 3-6.  The accuracy of Naïve Bayes 
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classification using leave-one-out cross validation is shown for each comparison 
is shown along with the p-value cutoff for each comparison.   
Table 3-6: Classification between each pancreas disease 
 
Notably at p<0.05, the differences between type 2 diabetes, pancreatic cancer and 
pancreatitis are small (< 2% of the peptides are distinct) while the difference 
between pancreatic cancer and panIN is <1%.  Between type 2 diabetes and panIN 
the differences were greater, at 15% of the peptides.  Between pancreatitis and 
panIN, 11% but we were able to achieve > 90% classification accuracy for each 
disease comparison.  These are the differences between net immunosignatures of 
pancreas related diseases. These differences come from various sources, it can 
come for either of the disease component or it can come from other components. 
To get more insight into the differences, the source of the difference in each 
comparison is calculated and shown in Figure 3-6. 
TheVenn diagram shows three overlapping sets. The left set shows the 
number of peptides that are 95% significantly different in the two diseases. 
Similarly, the right and the bottom set show peptides that are 95% significantly 
different in each disease and its common controls. As described earlier, peptides 
which are significantly different in a disease with respect to the common controls 
are the ones which make the disease component or uniqueness. Differences 
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between disease and the common controls at 95% confidence interval, varies by a 
huge amount. These differences comprises of uniqueness component. It is 92 
peptides for type 2 diabetes, 258 for pancreatitis, 1032 for pancreatic cancer and 
lastly 1696 for panIN.  
 
Figure 3-6: The source of differences in net immunosignatures of pancreas 
related disease at 95% confidence interval. (A) shows the Venn diagram of 
difference between 2 pancreas diseases and their difference from common 
controls. (B) summarizes the each component 
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In the 2.62% difference between the net Immunosignature of type 2 
diabetes and pancreatic cancer, only 2% is type 2 diabetes unique, and majority 
(73%) is pancreatic cancer unique. Hence the small difference that type 2 diabetes 
and pancreatic cancer have, it is due to peptides that are highly specific to 
pancreatic cancer. In the 1.34% difference type 2 diabetes and pancreatitis, only 
13% is due to type 2 diabetes unique signatures and 43% is due to pancreatitis 
signature. Hence, overall the differences between type 2 diabetes and pancreatitis 
is primarily due to the peptides, which are specific to pancreatitis. In the 
significantly large difference (15%) between type 2 diabetes and panIN, only 1% 
is due to type 2 diabetes unique signatures and about 69% is due to peptides, 
which are specific to panIN. Hence it signifies, the differences between the type 2 
diabetes and panIN is largely due to the peptides, which are specific to panIN. In 
the 2.44 % difference between pancreatic cancer and pancreatitis, about 11% 
difference is to pancreatitis signature and 44% is due to peptides unique to 
pancreatic cancer. Hence the majority of the difference between pancreatic cancer 
and pancreatitis is due to other components and pancreatic cancer unique 
signature. In an extremely small difference (0.46%) between pancreatic cancer 
and panIN, 71% of the difference is to the peptides specific to panIN and about 
20% of the difference is due to pancreatic cancer. Hence the small difference 
between the pancreatic cancer and panIN is due to panIN unique signature. Lastly 
the significantly large difference between the pancreatitis and panIN signature is 
to peptides specific to panIN (64%) and a very small difference (4%) is 
contributed by pancreatitis unique signature.  
 89 
Here we quantified the differences between each pancreas disease and 
respective component contribution in each difference. Type 2 diabetes unique 
signatures contribute significantly less in the difference from the other pancreas 
disease. Pancreatitis uniqueness only dominates when compared to type 2 
diabetes. PanIN uniqueness always dominates over the other disease uniqueness. 
In order to get commonality among these diseases, we compared each pancreas 
disease signature pairwise.  
 
3.4.8 SIMILARITIES AMONG DISEASE COMPONENT OF PANCREAS 
DISEASE 
The top 200 features that distinguished each disease component from 
controls were identified, regardless of the p-value cutoff.  Combinatorially, the 
probability of seeing r or more peptides among 200 from each disease component 
by chance is obtained from equation 1, where r is the set of peptides selected to 
distinguish any given comparison, p is number of peptides selected out of total 
(200) and n is total no of peptides (10,000).  For r > 10, this probability is <1%. 
Probability of r or more peptides is given by Equation 1.   
Equation 1: Probability of selecting r or more peptides by chance 
 
This equation can simply be derived from simple permutation and combination. 
We substituted r=10,000 and p = 200 and varied i=0 from 11 to come to more 
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than 95% significance level. Table 3-7 shows the probability of selection of r or 
more peptides by chance for this case. Hence the probability of having 11 or more 
peptides in common is just 2.6%, which is greater than 97% significance level. So 
if we see more than 11 peptides in common, its highly likely that these two 
diseases share something in common which is not by chance.  
Table 3-7: Probability of selection of r or more peptides in common while 
selecting 200 peptides twice from pool of 10,000. 
 
 
Figure 3-7 (D) shows that when we compared two unrelated disease like 
Alzheimer’s unique versus H1N1, valley fever, tularemia, and influenza there are 
about 1-10 peptides, which are in common, which would occur by chance. Also 
when we compared T1D that happens in kids and flu in mice, we got 3 peptides in 
common among 200. Hence seeing 10 peptides or less in common out of 200 can 
be purely accidental. Hence no significant conclusions can be drawn in these 
cases. (C) shows the binding of peptides among 200 in each disease uniqueness. 
This can also be seen from heatmaps for every pancreas disease. For type 2 
diabetes, 195 out of 200 peptides were high binders. 74 peptides are high binders 
in pancreatic cancer and 61 peptides are high binders in pancreatitis. In panIN 
only 28 peptides that are high binders. (A) and (B) shows the overlap between 
two diseases uniqueness. Among the 200 peptides for each disease, 22 peptides 
were common in type 2 diabetes unique and pancreatic cancer unique. Out of 22 
peptides, 21 were high binders and 1 was low binders compare to expression in 
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common controls. Having such peptides in common is much above the 
significance level and reveals there is some common signature in two diseases. 22 
peptides in common that are high binders in both the diseases signify that these 
peptides can be mimitopes of the same antigen. Comparison of type 2 diabetes 
unique and panIN unique reveals that there is one peptide in common which may 
be highly due to chance as seen from the Eq. 3.3.1. Also type 2 diabetes and 
pancreatitis have only 8 peptides in common which is likely due to chance. There 
are 50 peptides that are common between pancreatic cancer and pancreatitis out of 
which most of the peptides are low binders. Also in pancreatic cancer and panIN, 
50 peptides are in common out of which only 9 peptides are up regulated and rest 
are down regulated. In pancreatitis and panIN, there are 24 peptides is that in 
common and all of these are low binders. This analysis shows that, type 2 diabetes 
only has significant common signature with pancreatic cancer and not with any 
other pancreas disease, hence in (B) the Venn diagram shows 17 peptides which 
were common in pancreatic cancer, panIN and pancreatitis, all of which were low 
binders and not present in type 2 diabetes. This analysis shows significant 
commonality in some of the pancreas related diseases. Also epidemiology 
supports the argument of that occurrence of one is correlated with another 
pancreas disease. In this line, taking this information from a diagnostic level to 
monitoring the level of pancreas disease, we considered to design a chip of 
peptides, which can be used to monitor people with pancreas related diseases. 
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Figure 3-7: shows the Venn diagram of each pairwise comparison for every 
disease, using 200 peptides selected by t-test.  (B) shows the Venn diagram 
for pancreas diseases 
 
3.4.9 TOWARDS A GENERAL DIAGNOSTIC OF PANCREAS 
RELATED DISEASE 
The pancreas diseases we have considered in this work show both certain 
unique components and also significant evidence of having some signatures in 
common. Here, we have considered each disease under one pancreas disease and 
uncover the potential to identify pancreas disease from common controls. To 
achieve this, we have considered two methods to select peptides that would be 
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appropriate to perform this task most efficiently. Here, we compared these two 
approaches and pick the best one that would be suitable for this purpose. 
Method A: Selection of peptides from t-test between pancreas diseases and 
common controls (2 classes) 
Method B: Selection of peptides from multiple t-test (4) between each disease and 
common controls (4 times 2 classes), which is identical to choosing from each 
disease uniqueness.  
For the first method, we labeled each pancreas disease as disease and 
performed a t-test and pick top 643 peptides (p<0.025). For the second method, 
we considered top 200 peptides from each disease uniqueness. Since there were 
some peptides that were in common, we got 668 unique peptides out of 800 
(200*4). Figure 3-8 shows the Venn diagram of peptides selected by these two 
methods. Only 50% of peptides are in common by these two approaches.  
This indicates that the peptides which are informative to classify a super 
set of diseases are different than that of peptides that are informative for 
identifying each subset of super set. This has a huge implication in biomarker 
discovery. In order to compare these two approaches, we compared their 
performance measures accuracy, specificity and sensitivity over ability to detect 
pancreas disease from common controls. 
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Figure 3-8: 1Venn diagram showing selection of peptides by t-test between 
pancreas disease and controls (method 1) and iterative t-test between each 
pancreas disease and common controls (method 2). 
 
Heat map for method 1 Figure 3-9 (A)(a) and method 2 Figure 3-10 (B)(a) shows 
that in method 1, peptides have high gradient of regulation between pancreas 
disease and common controls. 
 
Figure 3-9: Heatmap, PCA and performance measures for method 1 
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The controls are more tightly clustered in method 1 compared to method 2. 
Principal component analysis of method 1 explains about 45% of the variance in 
two components while that of method 2 explains about 40% of the variance. The 
samples are almost equally separated in both the principal component analysis but 
method 1 is better due to higher percentage of variance explained. Figure 3-9 and 
Figure 3-10 (c) (d) shows the performance measures and classification table in 
which method 1 is better than method 2 in all the measures including accuracy, 
specificity and sensitivity. Hence method 1 is overall better than method 2 in 
finding the peptides to detect pancreas disease and controls.  
 
 
Figure 3-10: Heatmap, PCA and performance measures for method 2 
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3.5 DISCUSSION 
We used immunosignaturing to examine different diseases that target the 
same organ, the pancreas.  We tested whether there was a general immunological 
affect that might render signatures from patients with pancreas disease very 
similar by looking for overlapping peptides.  We found a distinct set of peptides 
that could classify each of the 4 diseases, but there were also peptides that were 
common across the 4 diseases.  We found that there were different numbers of 
peptides that were in common across the 4 diseases and different numbers of 
peptides that were uniquely personal to each patient and different numbers of 
peptides that were unchanged within the disease class. 
Initially we investigated whether each disease was distinct compared to 
healthy controls.  We obtained >95% specificity on average (93.75, 93.8, 100, 100 
for type II diabetes, pancreatitis, panIN and pancreatic cancer respectively).  Next 
we tested whether each disease was distinct from each other, and in this case we 
obtained >90% classification accuracy.  We thus show that each disease, although 
affecting the pancreas to some extent, also has unique immunological 
characteristics. 
We then looked for similarities between each pancreas disease.  The 
disease component (the part of the signature that defines the uniqueness of each 
disease) was used to examine the commonality between type 2 diabetes and 
pancreatic cancer.  These two diseases share a significant portion of this 
component, perhaps caused by common immunological stimuli.  All the common 
peptides were up compared to controls, suggesting common antigens.  Similarly, 
 97 
there was significant similarity across pancreatic cancer, pancreatitis and panIN.  
All common peptides were down compared to controls suggesting that there may 
be some immune suppression in these diseases.  The different pancreas diseases 
have their own unique signatures but also share portions of their ‘common 
component’ (component 2).  The third component (personal variation) was found 
to contribute differently across the diseases.  This component is important when 
using immunosignaturing for monitoring health status over time.  The patient 
uniqueness was established as those peptides which differ from person to person, 
excluding the disease specific (component 1) and housekeeping or ‘normal 
component’ (component 2) peptides.  We found that a range between 60 and 85% 
of the total 10,000 different peptides were individual specific (component 3) when 
examining these 4 diseases. 
Finally, in order to establish the potential of this technology for creating a 
diagnostic, we tested whether mixing peptides specific to a number of diseases 
would detrimentally affect the classification performance.  We chose 643 peptides 
that differentiate these 4 diseases.  These peptides could be printed on a 24-up 
microarray, which allows much cheaper per-assay cost and far higher throughput.  
Mixing the most informative peptides for distinguishing each disease from 
controls and from each other yielded >90% classification accuracy.  The fact that 
a pattern of peptides can be found that reliably distinguishes a disease from 
unrelated individuals is remarkable, but the presence of at least 3 distinguishable 
components within that signature lends credence to the fact that antibodies are 
highly tuned to the health status of an individual. 
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CHAPTER 4 FUSION EFFECT OF CARDIO VASCULAR 
COMPLICATIONS ON TYPE II DIABETES IMMUNOSIGNATURE 
4.1 ABSTRACT 
Immunosignaturing technology has allowed capturing the humoral 
immune response through binding of antibodies to random sequence peptides. 
Profiles of the antibody repertoire produced during any single infection or during 
long term chronic disease have proven to be unique, reproducible, stable and 
consistent across the diseased population. Every disease by itself has a unique 
immunosignature specific to its immunological binding of antibodies during its 
course. But in practice, individuals are often exposed to multiple diseases thereby 
potentially confounding the antibody binding to random sequence peptides. An 
important unanswered question relative to this technology is what is the net 
profile of the antibody repertoire when two diseases or infections fuse together 
biologically in a single person. Cardiovascular complications such as CHF and MI 
are often accompanied with type II diabetes (T2D) or vice versa. In this work, we 
obtained the immunosignature of subjects suffering from T2D and cardiovascular 
complications exclusively and then compared it with the immunosignature of 
subjects having both T2D and cardio vascular complications to observe the net 
effect of immunosignature when both the complications are fused biologically. 
We found, that immunosignature of T2D and cardiovascular disease were 
consistent and we were able to achieve 100% sensitivity when compared with 
common control group. The immunosignature of biologically fused mix of T2D 
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and heart complications was moderately consistent and unique, yielding only 
81.25% accuracy. When tested for interaction for the two complications as 
disease factors by 2 way ANOVA, the interaction was highly significant p<0.001 
indicating the non orthogonality of two immunosignature. Overall, the signature 
of the mixture of the two complications was different to the original 
complications, thereby resulting in a new complication with respect of their 
immunosignatures. 
4.2 INTRODUCTION  
Serological diagnostics biomarkers have received increasing scrutiny 
recently (Kurian et al. 2007) due to their potential to measure antibodies rather 
than low abundance biomarkers. Using antibodies as biomarkers solves the 
biomarker dilution problem, moreover these molecules are recruited rapidly 
following infection, chronic or autoimmune diseases, or even exposure to cancer 
cells (Ada and Jones 1986; Brichory et al. 2001; Cox et al. 1994; Fineberg et al. 
2005). Using antibodies as serological diagnostics biomarkers can reduce medical 
costs and may be the one of the best methods for early diagnostic. 
Immunosignaturing is one such technology that aims to detect disease early 
accurately. The platform consists of a peptide microarray with 10,000 peptides 
per assay. For every disease that we have tested we have a found a unique, 
consistent and a reproducible pattern of immunosignature that can be used for 
predicting new test cases. As a control study, this unique pattern of diseases has 
been obtained from a tightly controlled study involving subjects with disease of 
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interest and matched controls (Brown et al. 2011; Chase, Johnston, and Legutki 
2012; Legutki et al. 2010; Restrepo et al. 2011). But in reality, many subjects 
often have two or more disease which might be due to correlation, causation or 
even by chance. Multiple diseases may often interact with each other and change 
the resultant profile of antibodies produced by the immune system. Since 
immunosignaturing technology profiles the humoral immune response by 
profiling the net antibody profile of a disease, it is imperative to know how the net 
profile/immunosignature would change when two diseases are mixed inside a 
person. Immunosignatures are obtained through sera or plasma containing the 
antibodies source. When two antibody sources of disease (sera/plasma) are mixed 
physically rather than biologically the net immunosignature changes since every 
antibody source concentration is now diluted to half. So if the two sources have 
identical antibody profile, the net sera mixture would look exactly the same as the 
individual ones but if this effect is no additive, or if there is an interaction 
between the two profiles, then the resultant mixture immunosignature would 
change. In earlier work on immunosignaturing technology, we have seen that two 
completely independent immunizations of KLH and PR8 in mice sera mixture 
immunosignature have the respective KLH specific immunosignature and PR8 
specific immunosignature (Stafford et al. 2012). But when two diseases would 
interact biologically due to correlation or causation, the sera mixture could also 
change. Another unanswered question related to the biological mixing and sera 
mixing of immunosignature is how similar would the immunosignatures be?   
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T2D is a chronic metabolic disorder due to high blood glucose 
accompanied with insulin resistance and relative insulin deficiency (Burgoyne 
1961; Hamilton 1953). One of the primary reasons for the cause of T2D is due to 
obesity which results in fat deposits (Ozcan et al. 2004). One of the long term 
complications from high blood sugar can include heart disease and strokes. Cardio 
vascular complications such as Congestive Heart Failure (CHF) and 
Mycocardinal infarction (MI) are results of interruption of blood supply to a part 
of the heart that causes it to die. These is primarily due to occlusion of coronary 
artery. When taken together, epidemiology studies have shown that T2D and 
cardiovascular complications are correlated (Haffner et al. 1998).  
In this work, we tested the hypothesis that the immunosignature of 
subjects having both cardiovascular complications (CHF & MI) and T2D 
(biological mixture) will be the sum of the immunosignatures of subjects having 
cardiovascular complications and T2D exclusively. We also tested a sera mixture 
(1:1) of T2D samples and cardiovascular samples resemble the signature of the 
biological mixture of subjects having both the complications.  
4.3 METHODS 
4.3.1 MICROARRAY 
The CIM 10k V.1 is a 1-up microarray containing 10,000 random 
sequence 20-mer peptides top and bottom attached via a maleimide reaction to the 
NH3 terminal sulfur of cysteine, creating a covalent attachment (Legutki et al. 
2010).  
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4.3.2 SAMPLES PROCESSING 
Plasma samples from subjects with T2D, CHF& MI, (T2D + CHF&MI) 
and   were stored at -80 C after which samples were aliquoted and refrozen at -20 
C. Samples were diluted at 1:500 in sample buffer containing 1XPBS, 0.5% 
Tween20, 0.5% Bovine Serum Albumin (Sigma, St. Louis, MO) and then applied 
to the array using the standard immunosignaturing protocol as mentioned (Legutki 
et al. 2010). Antibodies were detected with 5nm Alexafluor 647-labeled 
streptavidin (Invitrogen, Carlsbad, CA). This tertiary antibody bind to 5nM 
biotinylated anti-human secondary antibody (Novus anti-human IgG (H+L), 
Littleton, CO). Microarrays were scanned and converted to tabular data after 
which median foreground signal was used as the value of antibody peptide 
binding.  
4.3.3 SAMPLES 
Center for Innovations in Medicine, Biodesign Institute, Arizona State 
University has an existing IRB 0912004625, which allows analysis of blinded 
samples from collaborators.  
We collected 11 plasma samples of subjects having poorly controlled type 
2 diabetes, 7 plasma samples having CHF&MI and 7 plasma samples of subjects 
having both T2D and CHF & MI related symptoms and 11 plasma samples of 
healthy controls.  
A plasma mixture is obtained by 1:1 dilution of two individual plasma 
samples of T2D and (CHF&MI) samples.  
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4.3.4 DATA ANALYSIS 
The raw tabular data were imported to GeneSpring 7.3.1 (Agilent, Santa 
Clara, CA). Data were median normalized per array and then transformed into  
log (10) scale.  
For feature selection (choosing significant peptides in each condition), we 
performed Welsh t test after multiple testing corrections (FWER=5%) to select 
peptides that are differential among the classes and then the analysis is performed. 
Line graph, scatter plot, principal component analysis and classification have been 
performed for supervised methods. For classification, we used Naïve Bayes with 
leave one out cross validation method since this algorithm has been known to 
work best for immunosignaturing data (Kukreja, Johnston, and Stafford 2012). 
For finding the interaction between the two disease factors T2D and (CHF&MI), 
balanced 2-way ANOVA is performed after multiple testing corrections (FWER= 
5%). 
4.4 RESULTS 
4.4.1 IMMUNOSIGNATURING OF DISEASE VS CONTROLS 
11 plasma samples of subjects having poorly controlled type 2 diabetes, 7 
plasma samples having CHF&MI and 7 plasma samples of subjects having both 
T2D and CHF & MI related symptoms and 11 plasma samples of healthy controls 
were run in duplicate in CIM 10k V.1 peptide microarrays. Technical replicate 
with Pearson’s correlation <0.90 were discarded. For each disease, approximately 
200 features are selected after Welsh t-test with multiple testing corrections. 
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Table 4-1 shows the classification accuracy; specificity and sensitivity for all the 
three complications when compared with common controls using Naïve Bayes 
leave one out methodology. For type 2 diabetes, 178 peptides passed the t-test at p 
<0.0025 and 93.75% accuracy was achieved. For cardio vascular complications, 
239 at p < 0.0005 informative peptides were selected after feature selection 
method yielding 95% sensitivity. For T2D and (CHF&MI), 234 peptides were 
selected at p < 0.01 yielding only 81.25% accuracy. Naïve Bayes treats features as 
completely independent source of information, which has advantages for a system 
like immunosignaturing where there is no biological connection across features. 
In order to test how different are each disease from each other, we tested all the 
three complications for their ability to discern from each other.  
Table 4-1: Performance measures for Immunosignaturing of disease vs 
controls 
Conditions T2D Vs Controls CHF, MI Vs 
Controls  
T2D & CHF, MI 
Vs Controls 
# of peptides          178
 ( p < 0.0025) 
      239 
( p < 5e-4) 
      234  
( p < 0.01)  
Accuracy 95 %  93.75 % 81.25 %  
Specificity 89.9 %  88.9 % 71.4 %  
Sensitivity 100 %  100 % 88.9 %  
 
4.4.2 IMMUNOSIGNATURING OF DISEASE VERSUS EACH OTHER 
Immunosignaturing of disease versus each other: Features that distinguish each 
disease from every other were identified using corrected t-test and presented in 
Table 4-2. The accuracy of Naïve Bayes classification using leave one out cross 
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validation is shown for each comparison along with the p-value cutoff for each 
comparison. Notably at p < 0.0005, the difference between T2D and cardio 
vascular disease were distinct with 100% accuracy; at p < 0.0005 the difference 
between cardio vascular immunosignature and T2D and (CHF & MI) 
immunosignature were distinct with 92.86 % accuracy. At p < 0.0025 the 
difference between T2D and type 2 diabetes, (CHF&MI) yielded only 83.33% 
accuracy using Naïve Bayes leave one out cross validation. The three 
complications were fairly distinct from each other; we then compared how many 
unique peptides for each complication are similar and whether unique peptides for 
individual complications are contained in the combined complication of T2D and 
(CHF, MI).  We selected 42 peptides from ANOVA (p-value <0.001) Figure 4-1 
shows principal component analysis showing 65% of the variance. 
Table 4-2: Performance accuracy of identifying complications from each 
other 
Conditions T2D Vs (CHF, MI) T2D Vs (T2D & 
(CHF, MI) 
(CHF, MI) Vs 
(T2D & CHF, 
MI) 
# peptides 148 ( p < 5e-4) 152 ( p < 0.0025 )  157 ( p < 0.0005) 
Accuracy 100 % 83.33 % 92.86 % 
 
 107 
 
Figure 4-1: PCA showing 42 peptides distinguishing three complications 
from controls 
 
4.4.3 SIMILARITIES AMONG COMPLICATIONS 
The top 200 peptides that distinguished each disease from controls were 
identified. The probability of seeing r or more peptides by chance common among 
200 from each disease is given by equation 1 discussed in chapter 2. For 10 or 
more peptides in common, this probability is less than 1% indicating non random 
or significant similarity between the two groups. Figure 4-2 shows 18 peptides 
that are common in T2D and (CHF, MI) immunosignature showing a significant 
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similarity in unique peptides that are specific to individual complications. 
Between T2D & (CHF, MI) and individual complications (T2D and (CHF, MI)) 
there are significant overlapping peptides (13 and 34) respectively. Overall each 
complication has significant overlap of peptides indicating similarity in each 
complication unique immunosignature. The unique peptides for the combined 
complication of T2D and (CHF, MI) had 82.5% (165) peptides non-overlapped 
with the two individual complications indicating a new immunosignature that is 
non-dependent on individual complications. We tested whether there is an 
interaction between the two complications T2D and (CHF, MI).  
 
 
Figure 4-2: Venn diagram showing top 200 peptides by t-test for each 
complication 
4.4.4 INTERACTION BETWEEN DISEASE FACTORS  
In order to test whether there is a significant interaction between the two 
disease factors (T2D and CHF, MI), we performed balanced 2-way ANOVA. 
Each cell among a total 4 cells contained 7 samples indicating presence/absence 
of each factors. Figure 4-3 shows Venn diagram indicating 245 peptides that 
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passed the test at p< 0.001 indicating significant interaction between T2D and 
(CHF, MI) immunosignatures. We then compared whether the combine 
complication immunosignature is similar to the physical mixture of individual 
disease plasma 1:1 mixture sample.  
 
Figure 4-3: Interaction between disease factors T2D and CHF, MI 
 
4.4.5 COMPARISON OF PLASMA MIXTURE AND BIOLOGICAL 
MIXTURE IMMUNOSIGNATURE 
We ran 4 plasma samples of subjects having T2D and (CHF, MI) on the 
CIM 10 K V.2 array in duplicates (biological mixture). 4 plasma samples each of 
T2D and CHF, MI are mix 1:1 to create 4 plasma mixture samples. Differential 
peptides were selected for biological mixture and plasma mixture population 
compared to healthy controls. Figure 4-4 A shows a Venn diagram of number of 
peptides that are common at p<0.05 significant level between biological mixture 
peptides and plasma mixture peptides. At this significance level, the plasma 
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mixture has >3 times more peptides than that of biological mixture 
immunosignature, although there are 70 overlapped peptides, the 
immunosignature of biological mixture and plasma mixture were quite distinct. 
Figure 4-4 B shows a principal component analysis for 134 peptides selected 
from a t-test between the two groups at p<0.025. The two classes can easily be 
separated by a linear line. Figure 4-4 C shows a Venn diagram indicating the 
peptides selected at p<0.01 for T2D and (CHF, MI) immunosignature, and at 
p<0.05 for plasma mixture immunosignature from the t-test between the 
individual group and common controls. 67% of the plasma mixture 
immunosignature non-overlapped with individual complications (112 / 167) 
indicating even the plasma mixture immunosignature cannot be obtained by 
individual components immunosignature.  
 
 
Figure 4-4: Comparison of biological mixture and plasma mixture 
immunosignature 
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4.5 CONCLUSION AND DISCUSSION  
We tested how the antibody profile interacts when an individual has two 
correlated disease using immunosignaturing technology. For a single disease 
course the profile of antibodies binding to random sequence peptides is unique, 
consistent and reproducible but when an individual suffers from another 
complication, there may or may not be interaction among the two antibody 
profiles. It is important to know how the biosignatures changes when a person has 
multiple diseases so that appropriate diagnostic measures can be undertaken if 
multiple diseases biosignatures are interactive to reduce false positive during 
diagnostics. In this work, we undertook two complications which are highly 
correlated; T2D and (CHF, MI) studied their immunosignature individually at 
first and then studied subjects having both the complications. Features were 
selected that differentiate subjects of T2D and (CHF, MI) from healthy controls. 
The immunosignature was consistent and reproducible and for both the cases 
classification sensitivity was 100% using Naïve Bayes leave-one-out 
methodology. The profiles of both T2D and (CHF, MI) when taken on an 
individual basis and compared to healthy controls produced a distinct 
immunosignature. But the immunosignature of subjects suffering from both the 
complications combined (T2D & (CH, MI)) were less consistent and the 
classification accuracy was lesser (81.25%) in predicting test cases compared to 
the immunosignature of individual complications. Since there was interaction 
between the antibody profiles between T2D and (CHF, MI) antibody profile, the 
net immunosignature of combined complication were less clear from control 
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group immunosignature. The peptides unique for the combined complication had 
only 17.5 % overlapping with the individual complication indicating a new 
immunosignature due to interaction effects. We formally tested for interaction 
between the two disease factors by 2-way ANOVA, significant interaction was 
found at p< 0.001. This interaction clearly suggests that the significant effect of 
immunosignature in the combine complication is due to fusion of antibody 
profiles between T2D and (CHF, MI) immunosignature. To test if this biological 
fusion can be obtained physically by mixing the antibody sources in 1:1, we tested 
plasma mixtures immunosignature of T2D and (CHF, MI) against subjects having 
both (T2D & CHF, MI). The plasma mixture immunosignature was completely 
different from the immunosignature of subjects having combined complications.  
When we tested for immunosignature of two immunizations in mice KLH and 
PR8 immunization, the net signature was simply an addition of the individual 
immunization, this is due to the fact the profiles of antibody of KLH and PR8 do 
not interact and these two immunizations are not correlated. So we suspect that 
whenever subjects will have more disease which are non-correlated, their net 
immunosignature would still contain individual disease immunosignature but not 
when the subject have two diseases which are correlated. Overall, we conclude 
that immunosignature for single disease is unique, consistent and reproducible but 
when two diseases which are interactive or correlated, the net antibody profile of 
the combine complication changes and cannot be obtained by profiles of 
individual diseases.    
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CHAPTER 5 DECIPHER SYSTEM TO TRACE RANDOM PEPTIDES IN 
IMMUNOSIGNATURE TO KNOWN PROTEINS IN TYPE 1 DIABETES 
5.1 ABSTRACT 
Infections or chronic diseases are accompanied by a humoral immune 
response that activates B cells to produce antibodies. Immunosignaturing captures 
the antibody repertoire of an individual at a given point in time. This is done by 
applying antibody source of an individual over unbiased probes of random 
sequence peptides thereby capturing their antibody profile whether that individual 
is healthy, combating a pathogen or is undergoing an immune response to their 
own defective cells.  Because the peptides used for this process are completely 
random, it may be that portions of actual epitopes are present within the 17mer 
peptide sequence.  As only 10,000 different peptides are used, it is unlikely that 
an extended identity exists. However antibodies have a unique way of imposing 
specificity.  We showed an unusual dipeptide inversion is possible when 
antibodies bind to peptides that carry some sequence similarity to the eliciting 
antigen.  There are likely many more ways that antibodies recognize epitopes in 
random peptide sequence space. Although there are biochemical methods of using 
the immunosignaturing peptides to capture disease-specific antibodies, these 
methods are quite time consuming.  It would be beneficial to capture as much 
sequence information as possible directly from the random peptides themselves.  
To this end we examined serum from patients with type I diabetes (T1D).  There 
are 3 well-known autoantigens for type 1 diabetes, but others are postulated to 
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exist.  We used an informatics approach to identify eight different protein 
candidates for T1D that are biologically consistent with the disease using only the 
10,000 peptides on our immunosignaturing microarray. If the correspondence of 
random sequence peptides from immunosignature can be made to the specific 
epitopes of the antigens, random sequence peptides could potentially be used to 
discover novel antigens for diagnostics as well as in drug discovery. We tested 
our ability to bioinformatically relate the peptides in the immunosignature of T1D 
to known and suspected autoantigens in T1D.  
We found immunosignaturing technology can separate T1D from controls 
with >90% specificity with 679 informative peptides. These differential peptides 
can be significantly mapped to 8 known and suspected antigens in T1D with 
<0.0001 false discovery rate and not to known random proteins (negative 
controls). In the mapping process of T1D immunosignature differential peptides 
to known and suspected antigens, there were 210 peptides whose intensities were 
higher and 479 peptides whose intensities were lower compared to controls. We 
showed that not only high binder peptides are mapped to the 8 antigens but also 
the low binder peptides are mapped against some of the antigens (3).  
Using GUITOPE, an epitope matching tool for mapping random sequence 
peptides to protein(s) we found significant mapping of our differential random 
peptides of immunosignature to known and suspected antigens in T1D. In the 
mapping process, we bioinformatically predicted the parts of 8 autoantigens in 
T1D where our differential random peptides are aligned (predicted epitopes).  
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We validated our predicted epitopes by spotting mapped regions of 
autoantigens in the form of 20-aminoacid non overlapping peptides on our arrays. 
We found significantly higher binding to our mapped predicted epitopes 
compared to random regions on the same autoantigens.  
We also tested the random peptides intensities which are mapped to IA-2 
and GAD-65 antigens in T1D subjects having high/low titers of respective 
protein. We found that these mapped random peptides showed significantly 
higher intensities in high titer subjects compared to low titer T1D subjects ( p 
value < 0.001)       
5.2 INTRODUCTION  
Biomarkers are a promising way for detection and diagnosing disease and 
could be the most effective means to improve human health (Weston and Hood 
2004). Towards efficient detection of biomarkers, hunt of high specificity 
diagnostics biomarkers for a particular disease is being performed by various 
methods and technologies. A persistent problem with this approach is that in 
reducing biomarkers to a few best candidates overtraining leads to fail one of the 
markers in large diverse populations (Kiehntopf, Siegmund, and Deufel 2007). 
One of the putative solutions to this problem is to use more biomarkers for 
diagnosing the disease of interest and that are less affected by genetics factors. 
We propose immunoglobulin molecules may solve this purpose. During an 
infection or chronic disease, antibodies are specifically amplified and are present 
in differentially abundant amount compared to a healthy person. It has been 
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shown that antibodies are produced during body humoral immune response which 
can distinguish non self antigens, altered antigens in autoimmunity like T1D (Ada 
and Jones 1986; Brichory et al. 2001; Cox et al. 1994; Sreekumar et al. 2004; 
Stockert et al. 1998).  
In order to observe the differential pattern in the antibody repertoire, we 
developed a machine-readable platform known as immunosignaturing, which 
profiles antibodies through random sequence peptides (Brown et al. 2011; Chase, 
Johnston, and Legutki 2012; Legutki et al. 2010; Restrepo et al. 2011; Stafford et 
al. 2012). Immunosignaturing works for any isotype and has detected cancer, 
infectious disease and autoimmune diseases. In order to control variability and 
cost, the random peptide microarray is commercially printed. Immunosignaturing 
has shown a high reproducibility (>0.95) between technical replicates.  
Immunosignaturing has made clear distinctions between disease and 
healthy controls, but we had not tested the idea whether the random sequence 
peptides have any detectable similarity to the real antigens involved in the 
disease. We tested an autoimmune disease in children. T1D is an autoimmune 
disorder in which the immune systems produces autoantibodies against self 
proteins like IA-2, GAD-65, ZnT8, Insulin, ICA-69 (Hawa et al. 2000; Leslie, 
Atkinson, and Notkins 1999; Urakami et al. 2009; Stayoussef et al. 2011; Lan et 
al. 1996; Bonifacio et al. 2000). It has also been shown that there is a significant 
suppression of the immune system in the T1D autoimmunity (Elo et.al 2010). 
This suppression can be general due to down regulation of genes like the HLA 
class I and II genes etc to prevent the ongoing autoimmunity (Elo et.al 2010). We 
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hypothesize that there might be some already existing autoantibodies against the 
self proteins in low concentrations at the normal state and when the autoimmunity 
is induced due to a specific autoantigen, this might activate the T regulatory cells 
in a constrained manner, there by turning the B cell off to reducing the already 
existing autoantibodies in the T1D people relative to healthy people (Colnaghi, 
Menard, and Porta 1977). ELISA type immune assays have been used to detect 
increases in autoantibodies to certain antigens, but as far as we know, have not 
been used to detect decrease in autoantibody levels relative to healthy controls.  
The immunosignature technology may be more facile than the current 
techniques in detecting both up regulation and down regulation of antibodies from 
the binding of random sequence peptides on our array. Figure 5-1 explains this 
phenomenon where a self protein/antigen causes an immune response that can 
lead to either an activation of B cells to reproduce and produce more antibodies 
specific to epitopes of an antigen or can regulate T-regulatory cells which can 
inhibit B cells in producing an already existing antibody against a specific antigen 
leading to lack of binding of these antibodies on our random sequence peptide 
array. We have earlier shown that an antibody raised against a particular epitope 
can also recognize random sequence peptide sharing significant identity or 
similarity with the epitope sequence (Halperin, Stafford, and Johnston 2011).   
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Figure 5-1: Pathway showing how a self protein/antigen can lead to up-
regulation and down-regulation of immunosignatures on the random 
sequence peptide microarray. 
In order to test our ability to map random sequence peptides to the real 
antigens involved in the disease, we attempted to bioinformatically relate the 
immunosignature of T1D to 8 known antigens. We validated these predicted 
peptides of by correspondence to Radio Immune Precipitation Assay (R.I.P) titers 
for IA-2 and GAD-65. We also mapped these predicted peptides onto the real 
proteins and spotted the predicted peptides of the protein in the form of short non 
overlapping 20 amino acid peptides onto our array to cross validate our 
hypothesis.  
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5.3 METHODS 
5.3.1 MICROARRAY 
CIM 10k V1 array is a microarray containing 10,000 20 amino acid 
random sequence peptides. These peptides create a covalent attachment via a 
maleimide reaction to the NH3 terminal sulfur of cysteine (Legutki et al. 2010). 
The CIM 10K microarray is available publically at 
www.peptidemicroarraycore.com 
 
5.3.2 SAMPLE PROCESSING 
Sera samples from T1D and controls were stored at -80oC. Samples were 
aliquoted and refrozen at -20oC. Samples were diluted at 1:500 for IgG detection 
detection in sample buffer (1xPBS, 0.5%Tween20, 0.5% Bovine Serum Albumin 
(Sigma, St. Louis, MO)) and run to the CIM 10K array. Tertiary antibodies were 
detected with 5nm Alexafluor 555-labeled streptavidin (Invitrogen, Carlsbad, 
CA). For IgG antibodies detection 5nM biotinylated anti-human secondary 
antibody (Novus anti-human IgG (H+L), Littleton, CO) is used. After processing 
the microarray was scanned and converted to tabular data as in (Legutki et al. 
2010). Median foreground signal was used as the value best representing binding 
of antibody to the peptide.  
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5.3.3 SAMPLES 
The Center for Innovations in Medicine, Biodesign Institute, Arizona State 
University has an existing IRB 0912004625, which allows analysis of blinded 
samples from collaborators. 
T1D and controls: This set contains 80 sera samples (39 diabetic children 
from age 6 to 13 and 41 samples of age-matched healthy controls). Radio immune 
precipitation (R.I.P) titers for IA-2 and GAD-65 for 40 samples of T1D were 
available.  
 
5.3.4 DATA ANALYSIS 
The raw data were imported to Gene Spring 7.3.1 (Agilent, Santa Clara, 
CA) after which it was median normalized per array and transformed to log10 
scale. We used Welsh t-test with family-wise multiple error correction (FWER) 
for feature selection. For multiple factor interaction, we used a balanced 2-way 
ANOVA with FWER. All p values presented are after FWER correction.  We 
used GUITOPE, an epitope matching tool to find degree of similarity of peptides 
to given protein sequence with 1000 iterations per comparison (Halperin et al. 
2012). The peptides having >1 score per alignment length was initially selected to 
plot against protein in GUITOPE. The peptides which indicated higher significant 
matching against the specific protein than the equivalent number of random 
peptides selected from the library (1000 iterations) were finally selected and their 
false positive rates were calculated. The false positive rate obtained from 
GUITOPE for these peptides represents number of times equal number of 
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peptides from the library showed the same level matching. For classification, 
Naïve Bayes and leave one out cross-validation was used due to its 
outperformance in immunosignaturing data (Kukreja, Johnston, and Stafford 
2012). Classification was performed in open source JAVA software WEKA (Hall 
et al. 2009).  
5.3.5 ANTIGEN SELECTION 
Table 5-1 shows 8 suspected T1D antigens and 8 random proteins have been 
selected for a match against T1D specific peptides. The sequence were 
downloaded from NCBI.   
Table 5-1: List of antigens selected for decipher 
Antigens/self protein for Type 1 
diabetes 
Random Protein 
IA-2  ACAA1 
IA-2 β ACOT1 
ICA-69 ACLS1 
Insulin ACSBG1 
GAD-65 AOX 
GAD-67 ALDH2 
GLUT-2 CoA 
ZnT8 CPT1A 
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5.4 RESULTS 
5.4.1 IMMUNOSIGNATURING OF T1D AND CONTROLS 
We ran 40 samples each of T1D and controls and selected peptides that 
are significantly different in T1D compared to controls. At p<0.0001 false 
discovery rate, we observed 689 differential peptides between T1D and common 
controls. Table 5-2 shows the classification accuracy, specificity and sensitivity 
for these differential peptides. We were able to achieve >90% specificity using 
Naïve Bayes classification algorithm leave one out cross validation though 
immunosignaturing. The distribution of the 679 differential peptides was skewed 
with only 210 peptides were high binders (peptides whose intensities are higher) 
and while 479 peptides were low binders (peptides whose intensities are lower) 
compared to controls. We then asked as to how many peptides bioinformatically 
can be mapped to the known antigens in T1D.  
Table 5-2: Performance measures of differential peptides in 
Immunosignaturing of type 1 diabetes 
 T1D  Vs Controls (IgG) 
No. of features  689 (p < 0.0001) 
Accuracy 88.75 % 
Specificity 92.3 % 
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5.4.2 BIOINFORMATICS DECONVOLUTION OF T1D  
IMMUNOSIGNATURE 
We first considered 210 high binder peptides in T1D, and bioinformatically 
mapped it to 8 known antigens in T1D using epitope matching tool GUITOPE. It 
has outperformed current existing epitope matching tools in regard finding not so 
near matches from complex random sequences to actual epitopes. The protein 
sequence for 8 known antigens was matched for sequence similarity with 210 
peptides using GUITOPE. The number of iterations was set to 1000 which 
signifies the number of times equal numbers of random peptides are selected from 
a 10k peptide sequence library to match against given protein(s). Net score is 
calculated by the GUITOPE output parameter score and alignment length by 
taking this ratio. Peptides showing significant matching on a region in a protein 
(epitope) over equal no. of peptides from our 10,000 peptide library at p<0.0001 
were selected. On average, we were able to successfully map peptides from 210 to 
known antigens with 1-2 possible epitopes per antigen with 3-4 peptides on 
average mapped to one epitope of an antigen. 7 peptides on an average were 
mapped against the antigen from a high binder set of peptides. Table 5-3 shows 
the number of epitopes, peptides per epitope and total peptides mapped per 
antigen for up regulated peptides from 210 peptides over 8 known antigens in 
T1D. Figure 5-2 shows the GUITOPE graphical representation of mapped 
peptides to the respective proteins. The red line indicates the average score 
obtained through selection of random peptides, the green peaks shows those 
regions significantly mapping peptides on a protein region. The number of peaks 
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represents the corresponding epitopes. With the assumption of at least single 
antibody binding an epitope, at least 14 antibodies correspond to binding of 
mapped high binder peptides and 210/56*14=52 antibodies correspond to total up 
signature.    
Table 5-3: Showing 210 high binder peptides from immunosignature mapped 
to 8 known antigens in type 1 diabetes. 
Protein  
Upreg.  
# 
Epitopes  
# Peptides-
E1  
#Peptides 
E2  
Total  FDR  
ICA-69  2  5  3  8  <0.0001  
GLUT-2  2  3  3  6  <0.0001  
GAD-67  2  4  3  7  <0.0001  
GAD-65  1  13  NA  13  <0.0001  
IA-2 β  2  3  4  7  <0.0001  
Insulin  2  3  4  7  <0.0001  
ZnT8  2  4  3  7  <0.0001  
IA-2  1  1  NA  1  <0.0001  
Total 14   56  
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Figure 5-2: GUITOPE analysis: mapping 210 high binder random peptides 
to 8 known antigens 
 
Next, we considered remaining 479 low binder peptides and mapped it against the 
known 8 antigens in type 1 diabetes. Our hypothesis behind this is presented in 
Figure 5-1. Table 5-4 shows the 479 low binder peptides from the T1D 
immunosignature mapped to 8 known antigens in T1D.  The low binder peptides, 
mapped to only GAD-65, ZnT8 and Insulin, which are the strongest antigens in 
T1D. The number of mapped peptides in the low binder set was higher compared 
to high binder set of peptides but the number of epitopes per antigen were similar 
for both up and down binder peptides. Peptides mapped to the antigens for two 
cases are indeed not only different since they are coming from two distinct sets, 
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but they also mapped to epitopes that are in different locations on the same 
protein sequence. Hence, a particular epitope of an antigen can result in high 
binding of peptides while other epitopes on the same protein can result in low 
binding of other sets of peptides. Figure 5-3 shows the GUITOPE graphical 
representation of mapped peptides to the respective proteins. The red line 
indicates the average score obtained through selection of random peptides and 
green peaks show significant mapping of these peptides on a protein region. The 
number of peaks represents the corresponding epitopes. With the assumption of at 
least a single antibody binding an epitope, at least 5 antibodies correspond to 
binding of low binder mapped peptides and 479/81*5=30 antibodies corresponds 
to total of down immunosignature.  
 
Table 5-4: Showing 479 low binder peptides from immunosignature mapped 
to 8 known antigens in type 1 diabetes. 
Protein  
Downreg  
# Epitopes  # peptides-
E1  
#Peptides 
E2  
Total  FDR 
ICA-69 - - - - >0.999  
GLUT-2 - -  - - >0.999  
GAD-67 - - - - >0.999  
GAD-65 2 25 17 42 <0.0001 
IA-2 β - - - - >0.999  
Insulin 2 9  14 23 <0.0001 
ZnT8 1 16 -  16 <0.0001 
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IA-2 - - -  - >0.999  
Total 5   81  
 
 
 
Figure 5-3: GUITOPE analysis: mapping 479 low binder random peptides to 
8 known antigens 
 
In order to set up a null control and method verification, we mapped 
differential peptides (both high binders and low binders) against 8 randomly 
choosen proteins from the human proteome, upon post selection we found some 
of the proteins are related to enzymes and none of them are involved in antibody 
production or T1D pathway. Table 5-5 shows the number peptides that were 
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mapped against set of 8 random proteins, which validates our method. Figure 5-4 
shows GUITOPE graphical representation of the mapped peptides to respective 
proteins. The red line indicates the average score obtained through selection of 
random peptides and green peaks shows significantly mapping of these peptides 
on a protein region. The number of peaks represents corresponding epitopes. For 
random peptides, no significant mapping was observed. In order to validate and 
verify our mapped peptides against known antigens, we did an orthogonal 
measurement by measuring intensities of mapped random peptides from T1D 
subjects sera.   
 
Table 5-5: Showing 679 differential peptides from immunosignature of T1D  
mapped to 8 random protein/antigens. 
Protein  # Epitopes  Total  FDR 
AOX - - >0.99  
ACAA1 - - >0.999  
ACSBG1 - - >0.999  
ACOT1 - - >0.999  
CPT1A - - >0.999  
ALDH2 - - >0.99  
CoA - - >0.99  
ACLS1 - - >0.99  
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Figure 5-4: GUITOPE analysis of 689 peptides to 8 random proteins 
 
5.4.3 ORTHOGONAL MEASUREMENT  
The GAD-65 titers using radio immuno precipitation assay had been 
independently measured on each of the T1D samples (Burbelo, Hirai et al. 2010). 
We asked if there is any correspondence between 13 mapped peptides intensities 
against GAD-65 and R.I.P titers. Figure 5-5 shows a box plot of average of 13 
peptides intensities on high and low titer GAD-65. There was a significant 
difference between the mean of the two groups (p <0.001). 
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Figure 5-5: Box plot showing average of 13 peptide intensity on 2 groups of 
T1D samples (high and low GAD-65 R.I.P titer. 
 
5.4.4 VALIDATION OF PREDICTED PEPTIDES  
Towards the goal of supporting the assignment of epitopes for the 
immunosignature, we mapped the random peptides specific to IA-2 and GAD-65 
to the real protein and select 17 amino acid non overlapping peptides of IA-2 and 
GAD-65 proteins and spotted them on our arrays. As a negative control, we 
selected other non mapped peptides on the same proteins. Figure 5-6 (A) shows 
the binding of T1D subjects on bioinformatically mapped peptides and non 
mapped peptides on GAD-65 protein. The predicted epitopes shows a higher 
binding for the predicted epitopes compared to the non-predicted ones for each 
individual T1D sample. Figure 5-6  (B) shows the average high binding of T1D 
subjects compared to control subjects on selected GAD-65 peptides. Figure 5-6  
(C) shows the similar pattern for IA-2 protein where only 1 T1D subject show 
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higher binding towards non predicted epitopes of IA-2 while the rest subjects 
shows that mapped epitopes have high binding than the non mapped for each T1D  
subject. Figure 5-6  (D) shows the T1D and controls binding on down regulated 
peptides of GAD-65, where controls subjects show higher binding than the T1D 
subjects. 
 
Figure 5-6: Testing of bioinformatically predicted epitopes on GAD-65 and 
IA-2 protein 
5.5 CONCLUSION AND DISCUSSION 
Immunosignaturing technology profiles antibodies during infection or chronic 
disease through interaction with random sequence peptides. Antibodies raised in 
response to a particular infection are captured by random sequence peptides 
having sequence similarity with epitopes of the original antigen. We have 
 132 
bioinformatically deciphered the information from random sequence peptides in 
case of T1D. We ran 80 samples (40 each T1D and controls). We found 679 
differential peptides at p<0.001(FWER) that were significantly different in T1D 
compared to controls. Out of these, 210 peptides were high binders and the rest 
were low binders. The significant part of the down immunosignature in T1D 
subjects is consistent with the gene level study done in a systematic differential 
expression on 520 probes which also had a high significant down regulated gene 
networks involved in T cell receptor and insulin signaling and antigen 
presentation (Elo et.al 2010).  
We then hypothesized that any antigen can potentially lead to either high 
or low peptide intensities in an immunosignature. Presence of an antigen during 
an autoimmune disorder like T1D can illicit immune responses and can either 
stimulate B cells to produce more antibodies against a particular epitope of self 
antigen which would lead to high binding of peptides in immunosignature, or it 
can stimulate T regs, for example, which can shut down B cells and hinder the 
already present autoantibodies against self protein and will lead to low binding of 
peptides of the immunosignature. This is based on the fact that the immune 
system already has autoantibodies present against the self protein but these are too 
low in concentration to elicit any autoimmune damage or being able to detect 
through normal ELISA. One of the other plausible reasons of the low binding of 
peptides in T1D might be a protective defense mechanism in autoimmunity to 
shut some regulatory biological pathways to prevent subsequent attack.  
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We used the immunosignaturing technology to examine whether antibody 
profiling through random sequence peptides have any congruity with clinical 
serological diagnosis of type 1 diabetes. We found using immunosignature we can 
separate T1D from controls by accuracy of 88.75%. We found suppression of IgG 
binding in 85% of the informative peptides that best separate T1D from healthy 
controls.  
We mapped these informative differential peptides from the T1D through 
immunosignature to the real antigens. Towards this bioinformatics deciphering, 
we took 8 known antigens in T1D and mapped both high and low binding 
peptides to these antigens using the epitope matching tool GUITOPE. This tool 
has outperformed the current tools in finding epitope of the antigens based on 
sequence on random peptides (Halperin et al. 2012). We calibrated the GUITOPE 
by selecting the best candidates according to score per unit length to remove false 
positives. Using the same deciphering method we did not detect any significant 
matching against 8 random human proteins as a part of negative control. 
In the mapping process, 210 high binder peptides were mapped to all 8 
suspected antigens with 1 or 2 epitopes per antigen. For some predicted epitopes, 
there were corresponding minimum of 3 random peptides while for others there 
were 15 peptides. On total there were 14 predicted epitopes with corresponding 
56 mapped peptides out of 210 that were mapped of high binder peptides to 8 
autoantigens. If we assume that at least one antibody would bind an epitope of 
protein, a total of 14 antibodies can be estimated from this data corresponding to 
the mapped peptides and total of 52 (210/56*14) antibodies for total differential 
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high binder peptides. Similarly while mapping low binder peptides, we found 
random peptides mapped to only 3 autoantigens with only 5 epitopes predicted in 
total. But for each predicted epitope in this case, there were significantly higher 
number of peptides (total of 81) that were aligned with epitopes possibly due to 
higher number of low binder peptides. Here 5 antibodies can be estimated for low 
binder mapped random peptides set but together 30 antibodies (479/81*5) can be 
estimated for down signature of T1D. Combining both the up and down 
immunosignature, a total of 82 (30+52) antibodies can be estimated from T1D 
immunosignature.      
Various analyses have been done on the antibody titers to 3 of these 
autoantigens IA-2, GAD-65 and insulin titers level. Clinical observation reveals 
frequency of IA-2 autoantibodies varies significantly with HLA genotyping and 
age (Hawa et al. 2000; Leslie, Atkinson, and Notkins 1999). It is known that it is 
highly persists one year after diagnosis and decreases after (Notkins and 
Lernmark 2001). We found two subgroupings in T1D subject’s immunosignature 
with respect to their IA-2 titers. The one group consists of low titers and the other 
consists of medium IA-2 levels and high IA-2 levels of titer. This is consistent 
with the above observation of the IA-2 high variability in T1D subjects. Being 
highly variable, immunosignatures of low IA-2 titers are significantly different 
from medium and high level IA-2 immunosignature while no significant 
difference exists between medium and high level titers.  Large studies 
determining the frequency of GAD-65 titers in T1D subjects have found that the 
GAD-65 to be less variable and highly consistent marker (Hawa et al. 2000; 
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Leslie, Atkinson, and Notkins 1999). This marker is known to be present at high 
levels consistently in T1D subjects. We observed similar pattern in subgrouping 
of T1D with respect to their GAD levels. The immunosignature of low and 
medium level GAD-65 titers are no different but these were significantly different 
between from high level titers (data shown in supplementary materials).  
IA-2 and GAD-65 are biologically distinct in function and their roles 
related to autoimmunity in type 1 diabetes. Clinically there is no observed 
interaction between IA-2 and GAD-65 biologically in terms of autoantibodies that 
are in common (Hawa et al. 2000). Using the immunosignaturing technology, we 
observed no interaction at 95% significance level using a balanced design two 
way ANOVA.  This shows the consistency between antibody profiling through 
immunosignature and clinical observation of IA-2 and GAD-65 independence 
(supplementary materials).  
We validated our decipher method by considering samples, which have 
high and low GAD-65 titer and measured 13 GAD-65 specific peptide intensities. 
There was a significant difference between the mean (shown in Figure 5-5) 
indicating an overall higher mean for high GAD-65 titers compared to low ones.  
We also validated our predicted random peptides of GAD-65 and IA-2 by 
mapping these peptides to real proteins. We selected the parts of the GAD-65 and 
IA-2 protein which were mapped by random sequence peptides, and spotted them 
on our arrays. We found that epitopes mapped by up regulated random peptides 
are higher binding in T1D subjects compared to other epitopes on the same 
protein. We also found the same result for down regulated peptides of GAD-65 
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where T1D subjects had lower binding compared to the controls, hence 
confirming our prediction. In this work, we showed how random peptides can be 
mapped the real antigens but the main potential of this technique can be extended 
to discover unknown protein to discover suitable drug targets. Differential 
peptides can be mapped back to the whole proteome and list of the matched 
antigens can be selected and validated to discover drug targets. Here by we 
conclude that immunosignaturing has potential for inexpensive diagnosis and be 
deconvoluted back to the known antigens of a disease and also can be used to 
discover new ones.  
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CHAPTER 6 FACTORS AFFECTING IMMUNOSIGNATURE 
6.1 ABSTRACT 
Immunosignaturing is a technology that captures the humoral immune 
responses to be observed through binding of antibodies to random sequence 
peptides. Unlike genomics, the immune system is believed to be more 
homogenous across a population. Using DNA, RNA or other genetic biomarkers 
poses a challenge to behave consistently across population in terms of detecting 
lot of variation in the people and hence prohibit these biomarkers to use 
universally. We propose, using immunological biomarkers may reduce some 
factors that vary across population like gender, age, location etc. 
Immunosignaturing assay profiles antibody responses of an individual at any 
given time based on the IgG antibody binding to random sequence peptides. An 
important unanswered question relative to this technology is what are the factors 
like age, sex, and geographical location that change or affect immunosignatures 
across the population? This question is of the clinical relevance while sampling 
populations for biosignatures discovery studies for immunosignature. If the 
factors can be known, an ideal sampling methodology can be formulated to screen 
populations based on these factors. We tested the immunosignaturing platform for 
its ability to resolve differences in age, sex and geographical location. We found 
the age is a very prominent factor that affects the immunosignature, with children 
under age 12 showing relatively high binding on our arrays. In contrast to the 
genomics markers, we found immunosignature of healthy male/female adults are 
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similar and no significant patterns is observed. For geographical location, we 
found there is a very significant difference among the US adult and Sweden 
adults, but no significant difference is found among immunosignature of people 
from different US states. Given, the fact that immunosignature is not bias against 
sex or local geographical location, this platform can be used very efficiently for 
broader screening for disease diagnostics biomarkers.     
6.2 INTRODUCTION 
Ideally a biomarker molecule that could diagnose disease early would be 
the most effective way to improve patient health (Weston and Hood 2004). 
Genetics biomarkers heavily rely on characterization of an individual like DNA, 
RNA, SNP (Lucas et al. 2009; Le-Niculescu et al. 2009; Kurian et al. 2007; 
Tugwood, Hollins, and Cockerill 2003). These biomarkers have been used for 
screening various diseases (Okamoto 2009; Hennessy et al. 2008) and this has 
been successful in many causes especially for single base pair diseases (Saiki et 
al. 1985). The basic problem with relying on the genomics biomarkers is they are 
very heterogeneous across population (Duffy, Evoy, and McDermott 2010; 
Sawyers 2008). The factors like age, sex and geographical location highly affects 
the traditional biomarker and thus are very prone to individual to individual 
variation (Rotimi and Jorde 2010; Emilsson et al. 2008; Millen et al. 2009). Were 
there a candidate biomarker that was relatively abundant, unaffected by age, sex, 
race or genetic factors, and different between healthy and sick persons and 
physically stable, the problem of biomarkers for effective diagnostic would be 
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much simpler. One such candidate, we propose are immunological molecules like 
antibodies might solve the heterogeneity problem. The immune system is known 
to behave more consistent and homogenous across a population compared to gene 
expression. Unlike basic DNA sequence which is static, the immune system is 
more complex and dynamic system which constantly monitors our health status. 
Antibodies are produced in both infection as well as chronic diseases like 
Alzheimer’s disease and cancer (Ada and Jones 1986; Brichory et al. 2001; 
Brydak and Machala 2000; Cox et al. 1994; DiFronzo et al. 2002; Hooks et al. 
1979). The signals from the antibodies during the course of any disease are 
amplified to a huge extent due to their ~1010 concentrations. We have developed a 
machine readable platform known as immunosignaturing which monitors the 
antibody binding to unbiased antigen epitopes through random sequence peptides. 
While we have seen clear distinction between disease and healthy controls 
immunosignature which were matched for age, sex and geographical location 
(Restrepo et al. 2011; Chase, Johnston, and Legutki 2012; Legutki et al. 2010; 
Brown et al. 2011), we had not tested the idea that immunosignatures might be 
quite similar for healthy individuals differ in age, sex and geographical location. 
We examined healthy individuals from of different age groups, geographical 
locations and sex one at a time while controlling for the other two factors. 
  
 140 
6.3 METHODS 
6.3.1 MICROARRAY 
The CIM 10k V.1 is a 1-up microarray containing 10,000 random 
sequence 20-mer peptides attached via a maleimide reaction to the NH3 terminal 
sulfur of cysteine, creating a covalent attachment (Legutki et al. 2010).  
 
6.3.2 SAMPLE PROCESSING 
Sera samples from healthy controls were stored at -80 C after which 
samples were aliquoted and refrozen at -20 C. Samples were diluted at 1:500 in 
sample buffer containing 1XPBS, 0.5% Tween20, 0.5% Bovine Serum Albumin 
(Sigma, St. Louis, MO) and then applied to the array using the standard 
immunosignaturing protocol as mentioned (Legutki et al. 2010). Antibodies were 
detected with 5nm Alexafluor 555-labeled streptavidin (Invitrogen, Carlsbad, 
CA). This tertiary antibodies bind to 5nM biotinylated anti-human secondary 
antibody (Novus anti-human IgG (H+L), Littleton, CO). Microarrays were 
scanned and converted to tabular data after which median foreground signal was 
used as the value of antibody peptide binding.  
 
6.3.3 SAMPLES 
The Center for Innovations in Medicine, Biodesign Institute, Arizona State 
University has an existing IRB 0912004625, which allows analysis of blinded 
samples from collaborators.  
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For testing age as a factor:  We collected 24 sera samples of healthy children 
from University of Arizona Asthma study were collected and 36 sera samples of 
local healthy adult donors from Biodesign Institute, Arizona State University.  
For testing gender as factor: We collected sera samples from healthy 7 males 
US adults and 14 females US adults from the Alzheimer’s disease study.  
For testing geographical location as factor: We collected sera samples from 
healthy 29 US Adults from local donors from Arizona State University and 23 
samples from Sweden Tularemia study.  
 
6.3.4 DATA ANALYSIS 
The raw tabular data were imported to GeneSpring 7.3.1 (Agilent, Santa 
Clara, CA). Data were median normalized per array and then transformed into 
log10 scale. To get an unbiased and unsupervised view of the immunosignature, 
first no feature selection was performed. If there is a bias in the unsupervised 
methods, we conclude that there is an effect of the factor, if there is no bias in the 
unsupervised methods, we performed Welsh t test after multiple testing 
corrections (FWER=5%) to select peptides that are differential among the classes 
and then the analysis is performed. Line graph, scatter plot, principal component 
analysis and classification have been performed for both unsupervised and 
supervised methods. For classification, we used Naïve Bayes with the leave one 
out cross validation method since this algorithm has been known to work best for 
immunosignaturing data (Kukreja, Johnston, and Stafford 2012) 
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6.4 RESULTS 
6.4.1 EFFECT OF AGE ON IMMUNOSIGNATURE 
36 US healthy adults and 24 US healthy children were run in duplicate on 
the CIM 10k V.2 peptide microarrays. Technical replicates with Pearson’s 
correlation coefficient <0.90 were discarded. Figure 6-1 (A) shows a line graph 
and (B) shows scatter plot of all 10,000 peptides intensity (normalized) for adults 
and children. The peptide intensity distribution for the children group was of 
significantly much broader range than that of adults. There were more than 2000 
peptides which were 2 folds higher in children compared to adults while there 
were less than 100 peptides which were 2 folds higher in adults compared to 
children.   
 
 
Figure 6-1 : Immunosignaturing of US Adults and Children 
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6.4.2 CLASSIFICATION PERFORMANCE ADULTS VS CHILDREN 
When tested for separating the adults and children groups using 
unsupervised methods, the two classes were distinct. Figure 6-2 (A) shows the 
principal component analysis for all 10,000 peptides explaining 38.13% of the 
variance in the population. The two classes can be very well separated with a 
linear line. (B) shows the classification table obtained from Naïve Bayes 
algorithm from all 10,000 peptides after leave one out cross validation. 98.34% 
accuracy was achieved with only 1 adult misclassified as children.    
 
Figure 6-2: PCA and classification table of adults vs children 
immunosignature 
 
6.4.3 EFFECT OF GENDER ON IMMUNOSIGNATURE 
7 US healthy male adults and 14 US healthy female adults were run in 
duplication on the CIM 10k V.2 peptide microarrays. Technical replicates with 
Pearson’s correlation coefficient <0.90 were discarded. From the unsupervised 
analysis, the two classes of males and females were not distinct and hence 
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supervised analysis was performed by selecting top 50 peptides from the welsh t-
test with 5% FWER. Figure 6-3 (A) shows line graph and (B) shows scatter plot 
of top 50 peptides intensity (normalized) for males and females. The peptide 
intensity distribution for both the groups were not significantly different and there 
was no specific pattern that can be observed regarding higher peptide intensities 
in any groups. 
 
Figure 6-3: Immunosignature of males vs females 
   
6.4.4 CLASSIFICATION PERFORMANCE OF MALES VS FEMALES 
When tested for separating the males and females groups using supervised 
methods (top 50 peptides), the two classes were not distinct. Figure 6-4 (A) 
shows the principal component analysis for top 50 peptides explaining 49.48 % of 
the variance in the population. The two classes cannot be separated with linear 
line and clustered together. (B) shows the classification table obtained from Naïve 
Bayes algorithm from the top peptides after leave one out cross validation. Only 
71.42 % accuracy was achieved (6 misclassification among 21 samples). The 
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difference between males and females immunosignature were not clear and 
subtle.       
 
Figure 6-4: PCA and classification table of males vs female immunosignature 
 
6.4.5 EFFECT OF GEOGRAPHICAL LOCATION ON 
IMMUNOSIGNATURE 
29 US healthy adults and 23 Sweden healthy adults were run in 
duplication on the CIM 10k V.2 peptide microarrays. Technical replicates with 
Pearson’s correlation coefficient <0.90 were discarded. Figure 6-5 (A) shows line 
graph and (B) shows scatter plot of all 10,000 peptides intensity (normalized) for 
US and Sweden adults. The peptide intensity distribution for Sweden adults group 
spanned significantly much broader range than that of US adults. There were 
more than 3000 peptides which were 2 folds higher in Sweden adults compared to 
US adults while there were less than 50 peptides which were 2 folds higher in US 
adults compared to Sweden.   
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Figure 6-5: Immunosignature of US vs Sweden Adults 
 
6.4.6 CLASSIFICATION PERFORMANCE OF US VS SWEDEN 
ADULTS 
When tested for separating the US and Sweden adults groups using 
unsupervised methods, the two classes were distinct. Figure 6-6 (A) shows the 
principal component analysis for all 10,000 peptides explaining 48.75% of the 
variance in the population. The two classes can be very well separated with linear 
line with few misclassifications. (B) shows the classification table obtained from 
Naïve Bayes algorithm from all 10,000 peptides after leave one out cross 
validation. 82.63% accuracy was achieved. Overall geographical location specific 
to country does make it an overall effect on the immunosignature. 
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Figure 6-6: PCA and classification table for US and Sweden adults 
immunosignature 
 
6.5 CONLCUSION AND DISCUSSION 
We used different factors like age, gender and geographical location to 
examine if these factors have any effect on immunosignaturing technology. We 
tested if children have different immunosignature than adults and found that the 
overall binding of antibody to peptide is very high on our arrays for children sera. 
The range of the peptide intensity binding was also high compared to that of 
adults. There are a few plausible explanations for observing high binding for the 
children sera. One of the explanations might be due to vaccination of children due 
to which they might have high immune response against random peptides. 
Another explanation might be that the children immune system are much more 
vibrant than that of adults since they are being less exposed to infections at the 
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early age. Since immunosignaturing technology measures the IgG antibody 
binding to the peptides, it might be possible the children have higher IgG 
antibodies in the first place.  
Using unsupervised methods, the difference between the immunosignature 
of children and adults are clear. The can be separated well from each other with 
>95% accuracy. Hence age as a factor affects the immunosignature to a 
significant extent.  
When tested for male and female immunosignature of adults, we did not 
find any clear indication of the difference using unsupervised methods. There was 
no significant difference between overall intensity of peptide binding on our 
arrays. When the top 50 peptides were selected that are differential between the 
males and females, the separation was not high and the two classes looked 
similar. In the principal component analysis, the males and females 
immunosignatures were clustered together and <75% accuracy was achieved in 
classify the two classes from each other. There have not been many reports 
indicating the difference in function of humoral immune response in males and 
females. This is one of the advantages of using proteomics biomarkers such as 
antibodies that are homogenous between genders. This would highly facilitate 
development of biomarkers that can be used for all the adult population 
irrespective of gender.  
We then finally test the effect of geographical location by comparing the 
immunosignature of US adults and Sweden adults population. We have seen that 
there is no significant difference of local geographical location like people from 
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Arizona, California etc (data not shown). But when cross countries 
immunosignature are compared, we found a significant difference between the 
immunosignature of Sweden adults and US adults. Sweden adults spanned much 
higher range of peptide intensities compared to US adults and the overall peptide 
intensities of binding was higher than that of US adults. In the unsupervised 
analysis using all 10,000 peptides, principal component analysis yield a good 
separation between the two classes with few misclassifications. The unsupervised 
classification yielded >80% accuracy between the two classes. Overall, the 
difference between the immunosignature of US adults and Sweden adults are 
clear. This might be due to several reasons possibly due to climate and life style 
difference.  
Finally, in order to establish the potential of this technology for creating a 
diagnostic, we tested factors like age, gender and geographical location for their 
affect on the immunosignaturing technology. Ideally in theory, this technology 
would eventually be used for health monitoring, a complimentary approach to 
diagnostics where every person would monitor their health status on regular basis. 
In that stage, the factors like age, gender and geographical location would no 
longer be of concern and all population variation would be normalized. But for 
more immediate use, it is extremely important and vital to understand the factors 
that would affect this upcoming immunosignaturing technology.   
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CHAPTER 7 TAKING IMMUNOSIGNATURING TEMPERATURE 
7.1 ABSTRACT 
The primary reason for the on growing health care crisis is due to post 
symptomatic medicine which relies on treating a disease after the person is sick or 
diseased. The major limitation of this approach is that the system in concern is 
already damaged and biologically, the concentration of antigens is very high. This 
in turn makes the system both challenging as well as expensive to repair. If this 
system is changed to pre symptomatic medicine, then the expense can be lowered 
to a significant extent as well the efficacy of the treatment methods could 
improve. In order to perform an early diagnosis rather than traditional diagnostics, 
it is imperative to establish a regular health monitoring system. One such 
upcoming technology that focuses on health monitoring is immunosignaturing. 
This technology profiles the humoral immune response through the binding of 
antibodies through random sequence peptides. Currently using 10,000 random 
peptides, this technology delivers an unbiased picture of the immune system 
creating a binding distribution of antibodies. Cells under the normal state are 
regulated but as soon as the body starts to enter a diseased state, the cells function 
starts to change, triggering the immune system.  We hypothesize that during the 
abnormal state of immune system, the profile of antibodies would change leading 
the change in distribution pattern of their binding to the random sequence 
peptides. If we were to take a measurement like temperature of the immune 
system on a regular basis, we could potentially detect any subtle changes in the 
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immunosignature of a diseased individual even if the specific cause were not 
known. We tested our hypothesis by taking Coefficient of Variation (COV) of all 
10k peptides of a healthy individual and compared it with diseased person on a 
population level. We found, that this measurement changed significantly in the 
disease group with sensitivity but not specificity. Also this measurement is stable 
over time, robust to protocol variation and even on the choice of 10k random 
peptides. Such unbiased mathematical and statistical measurements would help 
taking an unbiased view of immune systems and possibly alarm individual for any 
infection or disease.    
7.2 INTRODUCTION 
Healthcare expenditure is rising every year with total $2.5 trillion spent in 
2010 alone in US (US Department of Health and Human Services 2010). About 
90% of the expenditure goes in maintenance to take care of sick and diseased 
people (US Department of Health and Human Services 2010). This is primarily 
due to post symptomatic medicine methodology that we currently follow. Here, 
we wait for the individual to get sick and then start the treatment. The main 
limitation of this approach is that at a later stage of any disease, the concentration 
of antigens (defective molecules) is very high and probability of inexpensive and 
normal methodologies to normalize the situation decreases. A paradigm shift is 
needed to move the approach of post symptomatic to pre symptomatic diagnosis 
or a prognostic approach. Towards this approach, we need a novel technology for 
regular health monitoring to capture significant change in the health status of an 
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individual. One such technology is immunosignaturing, which profiles the 
humoral immune responses through binding of antibodies to random sequence 
peptides. Antibodies can be used as biosignatures of an individual’s health 
through observing their binding affinity on random sequence peptides. These 
random peptides have no homology with known epitopes, so they provide an 
unbiased profile of antibodies binding representing an individual immunological 
status.  
The immune system in a normal state has a profile of antibodies that are 
produced during a healthy stage of an individual. When this person encounters a 
foreign antigen or self-abnormal activity, this profile would change indicating an 
alarm. Immunosignaturing technology can provide a health status monitoring tool 
in this case to measure the antibody profile at a normal stage and alarm when the 
profile of antibodies change during a disease state.Using a machine-readable 
platform, both healthy and diseased individual signatures can be obtained from 
the antibodies binding 10,000 random peptides. The challenge now is to obtain a 
single measurement out of 10,000 random peptides that is equivalent to taking a 
temperature of the immune system to monitor abnormal activity.  
We tested the hypothesis of using a single metrics to measure the overall 
measure of antibody binding to 10k random peptides at a particular given time 
using immunosignaturing technology. Such metrics should incorporate several 
criteria. Firstly it should be independent on the choice of 10k random peptides for 
the unbiased measure. Secondly, it should be stable over time in an individual and 
also robust to protocol variations in the technology and thirdly it should change 
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significantly in diseased group or when the person is having infection or chronic 
condition. Developing such metrics is both useful and challenging. Here, in this 
work we tested one such metrics Coefficient of Variation for its efficacy to 
achieve above milestones.  COV by definition is just the inverse of signal to noise 
ratio. It is calculated by measuring the standard deviation over mean. The prime 
rational behind using this metrics is that when the immune system is in a normal 
state, the distribution of antibodies binding to random peptides will have some 
have some specific chaotic behavior. This pattern is likely to change; either 
becomes less chaotic, due to the antibodies generated towards a particular antigen 
or becomes more chaotic if several types of antibodies are raised against multiple 
complex sets of antigens. Measuring such distributional behavior in normal and 
disease conditions, antibody activity would eventually lead us to a measure that 
can diagnose disease conditions.  
7.3 METHODS 
7.3.1 MICROARRAY 
The CIM 10k V.1, V.2 AND V.3 is a microarray containing 10,000 
random sequence 20-mer peptides attached via a maleimide reaction to the NH3 
terminal sulfur of cysteine, creating a covalent attachment (Legutki et al. 2010). 
7.3.2 SAMPLES PROCESSING 
Sera samples from healthy controls were stored at -80 C after which 
samples were aliquoted and refrozen at -20 C. Samples were diluted at 1:500 in 
sample buffer containing 1XPBS, 0.5% Tween20, 0.5% Bovine Serum Albumin 
 154 
(Sigma, St. Louis, MO) and then applied to the array using the standard 
immunosignaturing protocol as mentioned (Legutki et al. 2010). Antibodies were 
detected with 5nm Alexafluor 647-labeled streptavidin (Invitrogen, Carlsbad, 
CA). The tertiary antibody binds to 5nM biotinylated anti-human secondary 
antibody (Novus anti-human IgG (H+L), Littleton, CO). Microarrays were 
scanned and converted to tabular data after which median foreground signal was 
used as the value of antibody peptide binding.  
7.3.3 SAMPLES 
The center for Innovations in Medicine, Biodesign Institute, Arizona State 
University has an existing IRB 0912004625, which allows analysis of blinded 
samples from collaborators.  
To test the effect of protocol variation on COV metric:  We collected 10 sera 
samples each of healthy and T1D children from the diabetes study and ran them 
under 1nm secondary IgG antihuman antibody and AF-555 as tertiary antibody. 
For another protocol, we collected non overlapping 30 sera samples each of 
healthy and T1D children from the same study and ran them after 6 months using 
5nm secondary IgG antihuman antibody and AF-647 as tertiary antibody.  
To test the effect of peptide array variation on COV metric: We collected sera 
samples from 7 healthy  US adults and ran them in both CIM 10k. V1 and V2 
using different set of 10,000 random peptides.  
To test the effect of time variation on COV metric: We collected 3 adults sera 
samples from Biodesign Institute, Arizona state university and followed their 
immunosignature on CIM 10k V.1 for 15 days with daily collection of blood.  
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To test the effect of early stage onset for COV metric: We collected 3 
biological replicates each pre and post influenza challenge.  
To test the consistency among normal group for COV metric: We collected 72 
sera samples of healthy individual collected from 5 different sources.  
To test measurement of Normal Vs Disease conditions on COV metric: We 
collected 14 samples of breast cancer, 23 samples of type 2 diabetes, 12 samples 
of Alzheimer, 5 samples of PanIN, 10 samples of pancreatitis, 19 samples of 
pancreatic cancer, 26 samples of esophageal cancer, 20 samples of GBM and 
finally 20 samples of Myeloma.   
7.3.4 DATA ANALYSIS 
The raw tabular data were imported to GeneSpring 7.3.1 (Agilent, Santa 
Clara, CA). Data were median normalized per array and then transformed into 
log(10) scale. To get an unbiased and unsupervised view of the immunosignature, 
no feature selection has been performed. Coefficient of Variation for each sample 
is calculated by taking the mean of the 10,000 random peptides over standard 
deviation of all the 10,000 random peptides. For each class, normal or disease, 
95% confidence interval has been constructed by taking 1.96 * standard error. 
Overlapping confidence interval indicates that the two groups mean difference is 
not significant.    
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7.4 RESULTS 
7.4.1 ANALYSIS OF COV ON PROTOCOL VARIATION 
We tested COV metric for its robustness for protocol variation on 
immunosignaturing technology. We tested subsets of disease and control samples 
collected from the same study, but processed under different time points and 
different secondary and tertiary antibody concentration. Immunosignature of 10 
sera samples each of T1D and controls were collected using 1nm secondary 
antibody concentration and AF-555 tertiary antibody concentration in the Set 1. 
For Set 2, we collected 30 sera samples each of T1D and controls from the same 
study. COV was calculated for every sample; mean and 95% confidence interval 
was calculated for both diseased group and controls for both the sets. Figure 7-1 
shows the mean and confidence interval for both the sets. Mean of COV in the 
diseased group between the two sets were not significantly different, and so was 
the mean COV of control group in the two sets. Although run under different 
protocol conditions, the measurements were stable and consistent among the two 
sets. 
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Figure 7-1: COV analysis for protocol variation 
 
7.4.2 ANALYSIS OF COV ON PEPTIDE ARRAY VARIATION 
We tested the COV metric for its robustness for the choice of 10,000 
random peptides on immunosignaturing technology. We tested subsets of 7 
healthy normal subjects on CIM 10k V.1 and V.2 consisting of non overlapping 
10,000 random peptides. Figure 7-2 shows the mean of 7 samples with 95% 
confidence interval for the two peptide arrays. The confidence interval for the two 
groups overlapped indicating there is no significant difference among the mean in 
the two groups between V.1 and V.2 CIM 10k arrays. 
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Figure 7-2: COV analysis on peptide array variation 
7.4.3 ANALYSIS OF COV ON TIME COURSE 
We tested COV metric for its consistency and stability over time on 
healthy individual subjects. Towards this goal, we tested 3 healthy individuals and 
followed their immunosignature for 14 days. Figure 7-3 shows mean of COV for 
each individual over 14 days time course and 95% confidence interval. For 14 
time points, COV was tightly regulated with <0.1 standard error. There was no 
significant difference among the three groups since the confidence interval 
overlapped indicating COV metrics is stable over time for healthy individuals. 
We then followed a subject (ID 43) immunosignature for 30 days during 
which subject has been vaccinated against tetanus at day 17, we tested if we could 
see any differences in mean COV of all 10k peptides for that subject. We found a 
slight increase after day 17 to day 24 in the COV after which this measurement 
stabilizes. Figure 7-4 shows COV measurement of subject 43 over 30 days.  
 
 159 
 
Figure 7-3: COV analysis of 3 healthy individuals on time course 
 
 
Figure 7-4: 30-day COV analysis on subject 43 and 84 
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7.4.4 ANALYSIS OF COV FOR EARLY STAGE DETECTION 
We tested COV metric for its ability to detect disease stage at an early 
onset. For this, we collected 3 mice and followed their immunosignature pre (day 
0) and post (14 days after the post influenza challenge). Figure 7-5 shows the 
mean of COV of pre and post immunized group with 95% confidence interval. 
There was a statistical significant difference between the two groups (p value = 
0.01) indicating the COV metrics changed at an early stage during the mouse 
immunization.  
 
Figure 7-5: COV analysis for early stage detection 
 
7.4.5 ANALYSIS OF COV ON HEALTHY POPULATION 
We tested COV metric for its consistency among different sets of normal 
population. We tested 5 different sets of healthy individual sera collected from 
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different studies across US. The group G1 consisted of 16 samples, G3 consisted 
of 11 samples, G4 consisted of 21 samples, G5 consisted of 10 samples and 
finally G6 consisted of 14 samples. Figure 7-6 shows mean and 95% confidence 
interval of mean of COV for 5 different groups. G1, G3, G5 and G6 were quite 
consistent with similar mean G4 COV had lower mean but all the overlapping 
confidence intervals indicated no difference among mean (COV) for the 5 groups. 
This shows that COV metric is tightly regulated in the healthy population. 
 
Figure 7-6: COV analysis on healthy population 
 
7.4.6 ANALYSIS OF COV ON DISEASED AND HEALTHY 
POPULATION 
We tested COV metrics for its differential ability in various disease 
populations compared to healthy individuals. Since COV metrics was consistent 
in different sets of healthy individual, it was combined into one set containing 72 
samples. For disease status, we compared healthy individuals ‘mean COV’ to 
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various infection and chronic diseases set. This includes various types of cancer 
like breast, pancreatic, myeloma, GBM and esophageal cancer. In other chronic 
diseases we compared the healthy individuals COV with type 2 diabetes, 
Alzheimer and panIN. For infectious disease, we compared it against pancreatitis. 
Figure 7-7 shows mean COV of normal and other diseased group with 95% 
confidence interval. In breast cancer samples, the overall immunosignature was 
highly suppressed and there was no significant difference found in mean COV 
between the two groups. Also in type 2 diabetes group, the mean COV between 
the normal group and type 2 diabetes group was not significant. Apart from these 
two, for all the other disease states, there was a statistical significant difference 
among the mean COV of healthy individual and disease groups. This shows the 
during disease state, COV metrics on the immunosignature tend to change 
significantly compared to normal state.  
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Figure 7-7: COV analysis on normal vs various disease immunosignature 
 
We tested COV metric for its ability to be sensitive to general diseases and 
relax the criteria for specificity. Towards this goal, we merged several related 
diseases like into one group. Breast cancer, pancreatic cancer, myeloma, GBM 
and esophageal cancer were grouped into one cancer group. Pancreatitis, PanIN, 
type 2 diabetes and pancreatic cancer were grouped under pancreas diseases. And 
finally all diseases were clubbed into one group known as diseased group. Figure 
7-8 shows the mean COV for healthy individuals, pancreatic disease group, 
Cancer group and finally the diseased group with 95% confidence interval. 
Healthy subjects COV were statistically different from any of the disease related 
groups indicating the COV metrics changes when the system is diseased and this 
metric is sensitive but not specific enough to predict which exact type of disease 
is encountered.  
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Figure 7-8: COV analysis of healthy vs general disease groups 
 
7.5 CONCLUSION AND DISCUSSION 
In this work, we proposed a diagnostic approach that can revolutionize 
healthcare using general monitoring of immune system by immunosignaturing 
technology. Immunosignaturing technology captures humoral immune response 
by binding of antibodies to random sequence peptides. When the immune system 
is in the steady or non-diseased state, we believe there is a general pattern of 
distribution of antibody binding in healthy individuals to random sequence 
peptides. This pattern is likely to change when the immune system encounters a 
self or non self attack due to the fact that antibodies will now be raised against a 
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certain epitope of the antigens and certain set of random peptides will be 
mimotopes of these antigens. Overall distribution pattern of diseased individual 
antibody peptide binding compared to healthy individuals will change. Towards 
this goal, we proposed that using Coefficient of Variation as a single metrics can 
be used as a temperature like measurement of the immune system on the 
immunosignaturing technology; this metric would change when a health 
individual gets sick.  
In gene expression studies, people hypothesized that cells under the 
normal state are tightly regulated, hence gene expression would be non chaotic 
but when a person enters a diseased state, the cells would enter into unsteady 
state, leading the gene expression to be more chaotic. But we observed an 
interesting phenomenon which may be different while working with immune 
system antibody profiles binding. When a person enters a disease state that have 
limited antigens like flu, or type 1 diabetes, we expect the antibody profile to be 
more tightly regulated since now immune system would produce antibodies 
specific to these limited antigens and hence the profile would be less chaotic. But 
when a person enters into a chronic condition or a disease responsible of several 
causes or antigens, then overall antibody profile would be diverge from normal 
behavior to a higher extent leading to chaotic behavior. We found COV of disease 
group in limited antigens diseases like T1D and flue as less compared to control 
group while the COV measurement of chronic disease like cancers were higher in 
disease group than that of control group.    
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For any single metrics per say, which would be an equivalent to take the 
temperature of immune system, there are several characteristics that this metric 
should achieve. We tested COV metric’s potential for these characteristics; we 
first tested this measure against protocol variation in the technology. We found 
that the COV metrics is very robust against protocol variation such as different 
concentrations of secondary and different types of tertiary antibody in the 
immunosignaturing technology. One of the major challenges in working with the 
growing technology is that there persists a continuous process of optimization in 
protocols. Such optimizations we believe should not hinder the choice of a single 
metrics and it should be robust against change in protocol variations and 
calculates the overall average pattern of binding of antibodies to peptides. 
Secondly we tested whether choice of 10,000 random peptides depend on the 
calculation of COV metrics, we found that this metric does not change 
significantly for the same individuals when they are tested in two different 
versions of CIM 10k arrays. Since the peptides are random, it is extremely 
important that any metric is not dependent on the choice of the random peptides. 
Thirdly we tested COV metrics stability over time during a un-disease state. One 
of the challenges of the microarray data is the noise and random variation, which 
affects the stability of any metrics. COV when tested over 14 days on healthy 
individuals, showed consistency in measurements. This is an extremely important 
characteristic in any metrics; this allows low standard error hereby enabling small 
changes in measurements to be significant. Apart from being consistent in an 
individual, it is also important that the metric should be consistent in a population; 
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this lowers the standard error in population and enables to deliver promising 
measurement over population studies. To test this, we tested COV metric on 5 
different non-overlapping healthy individual’s sera sample sets collected from 
different sources. We found, no significant difference in the mean COV among 
the groups. This facilitates the use of COV metrics on population level studies.    
One of the major goals of the prognostic approach is to detect any 
infection/chronic disease at an early stage; hence we tested the efficiency of COV 
metrics for its ability to change significantly in a mouse model. There was a 
significant difference between COV of pre and post mice; after 14 days of 
influenza challenge. This shows this metric has the potential to be able to 
incorporate early disturbances in immune system during infections. Moreover, we 
tested the ability of COV metrics to be able to differentiate among healthy and 
chronic diseased conditions. We calculated COV of 72 healthy individuals and 
compared it against various diseased groups like different types of cancers, 
Alzheimer’s etc and found a significant difference between mean COV of healthy 
individual’s vs diseased groups. Overall, mean COV of healthy individuals was 
lower compared to any diseased groups. This indicates that when the immune 
system is diseased, it becomes more chaotic due to antibodies produced against 
various antigens during a disease state. In the normal state, antibodies binding to 
random peptides are spread uniformly and usually unbiased for any particular 
epitopes or mimotopes. When the system goes into the diseased state, antibodies 
are generated against a particular epitope of the antigens, and random peptides on 
our arrays may be mimotopes for some of the antigens, which lead to more 
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diverse signals towards these mimotopes. Due to this, the overall chaotic behavior 
increases and mean COV rises in diseased individuals compared to healthy. Since 
COV only calculates the overall behavior of binding, it is not specific to disease 
conditions; hence we saw no significant difference between mean COV between 
disease groups alone. Hence, this metric is sensitive but not specific for predicting 
the type of diseased condition.   
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CHAPTER 8 CONCLUSIONS AND FUTURE WORK  
Health related concerns, be it social, economical have been always an 
inseparable part of our society. With modern education and resources, people are 
becoming more aware of the importance of health in our lives. Improvements in 
technology have created methods, tools and devices that have significantly 
impacted both our life-style and age in a positive way. But at the same time, our 
efforts on improving health care have been depleting our finances to a 
significantly higher extent. If examined carefully, these expenditures are largely 
hospital bills of people who are already diseased. This is basically the cost of post 
symptomatic medicine methodology that we currently follow in our society. Due 
to lack to appropriate technology and ideas, there aren’t many institution or 
research centers that are pursuing research towards pre symptomatic medicine. 
For most of the people, early diagnostics often means to detect the early 
recurrence of disease symptoms or cancer tumors so it is a bitter truth that early 
diagnostic has lost its name in reality. Another road block for early diagnostics 
research is there are not many technologies or research that are focusing truly on 
pre-symptomatic methods and thus this field, although very powerful, has been 
ignored by our society unconsciously.  
There are two complementary approaches for adopting pre-symptomatic 
medicine methods; first is in the discovery of early diagnostic biomarkers and the 
second being able to monitor health monitoring on regular basis. The goal of 
discovering early biomarkers as been supported for the last 30 years and trillions 
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of dollars has been spent on the approach of finding single, early biomarkers in 
the population. Mass spectrometry showed the most promise in delivering 
biomarkers but attempts were not significant since the population was 
heterogeneous and sample preparation was laborious and cumbersome. To date 
we only have 47 FDA approved biomarkers. The major problem of the approach 
to date is the basic process of discovery that is too conservative. The approach 
generally starts with 10:10 disease/control samples with a highly homogenous 
population and then researchers screen for significant differential biomarkers in 
the 10:10 sample study. The candidates are pushed in next stage of 100:100 
disease control study and so on. But as the study progresses, the candidate 
biomarker molecules tend to fall out due to the problem of finding a single 
element in a heterogeneous population.  
Lately health monitoring has been getting increased attention but there is a 
big technological limitation of doing a health monitoring. Most of the 
technologies, apart from Immunosignaturing, I am aware of are not well designed 
for health monitoring. The biggest reason why other technologies are not able to 
focus on health monitoring is due to their focus on assaying a single disease. For 
health monitoring, our focus should be unbiased against choice of biological 
elements but at the same time our choice of elements should be appropriate. So to 
achieve perfect balance in terms of getting unbiased as well as early obtaining 
individual normalized biosignatures is to use antibodies as biomarkers in the form 
of a random peptide microarray. Immunosignaturing has its root in traditional 
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microarray with DNA fragments replaced with random peptides. This allows 
specific and sensitive measurement of immune system of an individual through 
binding of antibodies to random sequence peptides.  
Immunosignaturing is different from traditional microarrays in terms of 
the complexities it captures; it is highly a complex multiplexed assay where a 
DNA microarray relies on one-to-one binding of molecule of interest to probes. 
The immunosignaturing microarray captures multi-level interactions. A single 
peptide on our array can bind to multiple antibodies and a certain antibody can 
bind to multiple peptides forming a many to many relationship. Hence, each 
peptide shows in the end, the resultant binding of multiple antibodies to it. This 
data is highly informative, but traditional methods, especially classifiers which 
worked for gene expression microarrays, may not be suitable for 
immunosignaturing data. So at first, I did a literature search for known and most 
commonly used classifiers and applied them on various immunosignaturing case 
studies. I tested 17 different classification algorithms on different datasets over 
multiple levels of stringency; the outperformance of Naïve Bayes was pretty clear. 
Some users of immunosignaturing data have found that the algorithm SVM tend 
to work slighter better than Naïve Bayes. But my studies have shown that overall 
Naïve Bayes outperforms in the long run and can be considered as gold standard 
if someone wants to stick to one classifier for the data analysis. The biggest 
variable on the choice of best classifier is number of features (peptides) that you 
want to select for your hypothesis. While some hypothesis are based on 
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diagnostics test, while others are based on narrowing down significant peptides 
from 10,000 to top 200 in pilot studies and using small set of peptides for larger 
sample sets. Some classifiers like LDA (Linear Discriminant Analysis) performs 
well in the number of peptides selected is less than 25; in short this classifier is 
good for a small number of features. So if a person runs his/her 
immunosignaturing case study against the LDA classifier for the top 10 peptides 
and found the accuracy greater than the Naïve Bayes classifier it does not imply 
LDA outperforms Naïve Bayes over the long run. I have shown that overall a 
classifier performance decreases when the number of features increases. Naïve 
Bayes performance does not drop drastically in this case yielding a consistent 
measure irrespective of number of peptides. Also Naïve Bayes has never shown to 
underperform in my immunosignaturing case studies. It has ranked second on 
some datasets but I have not seen more than 10% difference between any 
classifier and Naïve Bayes performances. The main reason I support the Naïve 
Bayes performance is due to its simplicity and a unique property of independence 
which is satisfied by the immunosignaturing design. Naïve Bayes classifier is 
based on Bayes rule which assumes independence of features. In real world 
applications of classifiers even in DNA microarrays, there is always some sort of 
dependencies on features. In the case of gene expression microarrays, they are 
connected via regulation networks with master and slave genes; hence the 
probability of Naïve Bayes working is low due to its assumption of feature 
independence violation. But in immunosignaturing, random peptides are 
completely independent of each other and there is no significant sequence 
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similarity we know between peptides. On this note, some people have argued 
about the independence of the peptide in immunosignaturing claiming it is not 
independent. When a monoclonal sera is run on our arrays there are multiple 
peptides that show signal in synchrony so they may be mimotopes of the same 
antigen so they are not independent. As simple as the argument sounds, it’s not 
completely true. As described the complexities of immunosignaturing design; 
each peptide signal is mixture of multiple antibodies binding, so although these 
peptides which are mimotopes might be correlated but they are often bound by 
other antibodies making the correlation less and more independent due to 
multiplicity. I think for a classifier the conclusion is pretty concrete that Naïve 
Bayes is very effective for immunosignaturing case studies. Overall performance 
of a classifier also depends on features selected, so more work can be done on 
feature selection methods apart from t-test to see if that increases Naïve Bayes 
performance. There are two parameters to consider. First are the feature selection 
methods, and second are classification algorithms. I used a single feature selection 
method and varied different algorithms to choose the best. Now when we know 
which classifier is best, future work can be extended to choose the best feature 
selection method for which Naïve Bayes performs the best.  The reason for I do 
not feel very confident in using the t-test feature selection methods is due to the 
fact that biosignatures study like immunosignaturing are based on heterogeneous 
data and t-test look for consistency in terms of peptides intensity in a class. So 
even in the disease group; some samples might be of another type, while other 
will be of other. For example, I saw in one the immunosignaturing case studies 
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was when I was analyzing type 1 diabetes data set. Although 40 samples were 
classified into one class T1D but based on their Radio Immuno Precipitation 
Assay titers, I found there was a sub grouping of subject’s immunosignature 
having high and low IA-2 titer. So what I observed was peptides that were 
specific to IA-2 did not get selected in the t-test since there measurements weren’t 
consistent across the disease group of T1D. Hence, a feature selection method 
should be adopted which also looks for sub grouping in the population and then 
look for consistency.      
Finding a right classifier was the very first and important thing I did for 
my immunosignaturing case studies. Analysis of immunosignaturing data in any 
hypothesis often demands classification among different conditions of interests, 
so Naïve Bayes algorithm came in handy while I was researching other 
hypotheses relative to the technology. When my center first pursed 
immunosignaturing, the biggest critique that we got from immunologist was that 
this technology would not be specific for a particular condition. Their expectation 
was that we would only see general inflammations responses. So my first goal 
was to find the resolution ability of immunosignaturing technology. The aim was 
to test the sensitivity and specificity of the immunosignaturing technology. So I 
pursued a case study involving closely related diseases in the pancreas (type 2 
diabetes, pancreatic cancer, pancreatitis and panIN). On immunosignaturing 
individual diseases and common a control group, it was clear that this technology 
was sensitive enough to detect the presence of disease with >90% accuracy when 
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tested on independent test sets. Then for specificity, I compared each disease 
immunosignature among each other and found >90% accuracy on separating each 
disease. It was clear that this technology was not only specific but also sensitive 
enough to detect the presence of closely related inflammation and chronic 
diseases in the pancreas. While studying this hypothesis, I realized a unique 
mathematical property of immunosignaturing data. I postulated that in a 
population study immunosignaturing data can be considered as a vector which has 
three orthogonal components at a certain significance value. The primary 
component being a disease component which is set of the peptides that changed 
significantly from the control group. The secondary component, I refer to as the 
‘normal’ or ‘house keeping component’ are the set of peptides that does not 
change significantly between the diseased and control group. The third 
component I termed as ‘individual variation’ are the set of peptides are unique for 
each individual and change according to personal variation. All the three 
components have their intrinsic value depending on the question in hand. The 
disease component is highly informative if we are studying diagnostics for 
disease, normal component play its role for quality control and providing a base-
line for population studies. The third component is important when we are 
studying health monitoring of an individual over time. Although my research 
question in the beginning was to test if this technology is sensitive and specific for 
chronic diseases, I leveraged my disease component data for the pancreas related 
diseases to test if there are any similarities among specific disease 
immunosignatures. Epidemiology studies have reported a correlation and 
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increased risk prediction of pancreas related disease if an individual already have 
another pancreatic disease (Noel et al. 2009). In specific there cases of individual 
having both pancreatic cancer and type 2 diabetes is pretty common. Although 
correlation between the two does not imply causation, researchers suspect that 
there might be some common biomarkers between the two diseases (Huxley et al. 
2005). In my immunosignaturing data of pancreas related disease, I found 
consistency with the literature findings. When the top 200 peptides for each 
disease are compared, there was a significant overlap between signatures of type 2 
diabetes (T2D) and pancreatic cancer. Also there was a significant overlap 
between signatures of T2D, pancreatic cancer and panIN which reveals that there 
is some common antigen driving the common signatures of these diseases. 
Harnessing this information, I proposed an idea of general monitoring of pancreas 
related diseases. Instead of taking each disease as individual disease, I proposed to 
take all diseases under one single disease and find the signatures that are 
consistent among all diseases. I found 673 peptides that had high specificity 
(>95%) on a test set which can be used for the general monitoring for pancreas 
related diseases. This study can be extended by considering peptides that are 
common in each disease component and decipher them for common antigen 
responsible for the cause.  
Immunosignaturing when tested for various diseases and infections shows 
promise since the signature was reproducible, consistent and unique for every 
disease tested. It is a general lab practice to initially look for a small set of 
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samples for disease and control. But in reality individuals often suffer from more 
than one complication, so we tested whether a disease immunosignature still 
remains consistent in the presence of another disease. When we tested subjects 
having type 2 diabetes and (CHF, MI) alone, their immunosignatures were 
unique, consistent and reproducible with 100% sensitivity obtained when 
comparing with healthy controls. But when I tested samples from people having 
both T2D and (CHF, MI), their immunosignatures had only a few features 
(peptides) in common with the individual complication. Apparently the presence 
of both diseases creates an interaction resulting a different immunosignature. The 
occurrence of these two complications are correlated and but some have even 
proposed a casual relationship (Haffner et al. 1998). When we tested the same 
concept on two diseases which do not interacted or correlated or in casual 
relationship like [(Cancer and flu), (KLH and PR8 immunization), we have found 
that even in the mixture of two diseases, individual disease immunosignature can 
be separated. Thus, if a subject is having multiple complications, 
immunosignaturing diagnostic for a single complication might still be reliable if 
multiple complications are not correlated or in casual relationship.  
 With successful attempts in classifying disease/conditions though 
immunosignaturing over the last few years, we developed confidence that this 
technology may have use as a diagnostic. But one thing which amazed almost 
everyone who has been encountered with this technology is the power of using 
random peptides. For some, it feels suspicious while for some it realizes that it 
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makes sense to be able to deal with the stochastic behavior of immune system 
with the use of random peptides. But everyone at first seems a little dubious to 
trust the power of random peptides. Initially we attempted to trace back random 
peptides by applying monoclonal antibodies on our arrays but we found that 
although monoclonal antibodies were raised against a particular epitope, these 
antibodies recognize other epitopes on our array (mimotopes). Later our lab 
developed a tool GUITOPE which is an epitope mapping tool for random peptides 
onto given protein(s). On working with the immunosignature case study of type 1 
diabetes, it occurred to me to work on tracing random peptides for T1D to its 
respective antigens. T1D has been studied well and 3 known autoantigens have 
been reported along with other candidate antigens. So I took T1D as a case study 
to trace random peptides to known T1D antigens. On a sample set of 40 disease 
and 40 controls, I found 679 peptides that were different in T1D compared to 
common controls. Out of 679 peptides, 210 were higher and 479 were lower 
significantly compared to controls. I observed that not only high binder random 
peptides were successfully mapped to 8 known antigens but also the low binder 
peptides were mapped to 3 known antigens in diabetes. We then hypothesized that 
there are already existing autoantibodies during the normal state against self 
proteins but modern technologies like ELISA are not that sensitive to detect at 
such low concentrations and when a person develops autoimmunity like T1D, the 
immune system may be trigger T-regulatory cells to shut down B-cells leading to 
lack of antibodies in the disease state which existed in normal state. Random 
peptides on our array mapped to certain parts of known antigens (predicted 
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epitopes). In order to test our prediction we spotted the real peptides 
corresponding to our mapped random peptides and found our prediction to be true 
for both high and low binder peptides. One key thing I noticed in the mapping 
process is when random peptides are mapped using GUITOPE, there is lack of 
specificity since random peptides mapped not only to known antigens but also to 
some random antigens. I calibrated the score of GUITOPE (described in chapter 
5) and found that now the peptides had a more specific behavior. One of the 
possible future works would be to test this calibration on other data sets and if 
successful incorporate that to GUITOPE. Another limitation I encountered during 
the mapping process is the required prior knowledge of antigens. Currently 
GUITOPE requires the input of a protein sequence, It would be best if a high 
throughput system can be designed which can automatically maps random 
peptides to the whole proteome for discovering unknown targets.  
 With the advent of immunosignaturing technology, the main idea our 
center had in mind was diagnostics but little different from what people having 
been doing so far in terms of looking at heterogeneous population rather than 
homogenous population. Although our aim is health monitoring of an individual, 
the technology also has data for population studies. One of the advantages of 
dealing with population data is the knowledge obtained from so many subjects 
immunosignature which helps in formulating the baseline. I collected all the data 
of healthy patients that were run in the past over our initially CIM 10 K V.1 
arrays and analyzed the patterns of 10,000 peptides in a normal population I call 
the ‘Standard Normal Signature’. During the analysis, I encountered very 
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interesting patterns in the 10k random peptides in normal population. While 82% 
of the peptides the reactivity was distributed as a normal distribution, there was a 
handful peptides that followed interesting distributions like uniform and bimodal.  
 Immunosignaturing relies on the immunological behavior patterns of an 
individual’s antibody repertoire. Unlike genetics, I feel immune system 
biomarkers are more homogenous in terms of their basic variation in the 
population. Since we were doing lot of population studies on immunosignaturing, 
I studied factors affecting immunosignatures like age, sex and geographical 
location. Towards the end of my thesis work, I became interested in the health 
monitoring aspect of immunosignaturing which relies on taking signatures of 
individual at regular intervals to warn against any aberrations in ones 
immunosignature. For this, we required a measurement like an immune system 
temperature that we can calculate through our technology. Before moving to a 
mathematical choice of measurements, I realized a behavior of the immune 
system which might be related from traditional genomics. In gene expression 
studies, cells are known to be tightly regulated and controlled hence regulating the 
genes that are expressed during a normal state of an individual but when a person 
is sick, the cell enters into a chaotic state making gene expression more scattered. 
Looking into computational metrics like context mining, researchers have 
classified a person as disease or normal looking into the chaotic behavior of gene 
expression studies. I proposed that this might also be true when working the 
immune system. When we are in a normal state, the immune system produces a 
normal set of antibody repertoire hence their binding pattern to random sequence 
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peptides would follow a certain distribution but when we suffer from disease this 
antibody repertoire distribution to random peptides would change. One of my lab 
members, Kurt proposed ‘Entropy’ as a single metric but I found it to be too 
averaged and did not significantly change when a person is exposed to a disease. I 
proposed ‘Coefficient of Variation’ as a simple metrics that might be useful to 
take a ‘temperature’ by immunosignaturing. This metric when I test on different 
case studies of immunosignaturing showed promise in changing significantly 
during a disease course, consistent in a normal population, and independent on the 
choice of random peptides. This is a very simple metric and in the future other 
computational and mathematical metrics should be tested as their potential to take 
temperature like measurements through our arrays.  
 While working on different case studies of immunosignaturing, I realized 
there is a great potential of this technology both as a population diagnostics, 
health monitoring as well as discovering drug targets. Since immunosignaturing 
has its roots in microarrays it is extremely useful to pay more attention to data 
analysis and developing mathematical and computational tools for efficient 
analysis of immunosignatures. In my Ph.D. work I laid out some ground work 
about unique potential of immunosignature and opened doors for other 
computational scientists to explore more interesting aspects of 
immunosignaturing.          
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APPENDIX 
A.TITER ANALYSIS ON T1D SUBJECTS 
We collected 29 samples of type 1 diabetes (T1D) having high IA-2 titer and 10 
samples having low IA-2 titer. We selected 57 peptides that were 2 fold higher in 
higher titer samples compared to low titer samples. Figure A.1 (A) shows 
heatmap of 57 peptides in high/low titer subjects. (B) shows principal component 
analysis where high and low titers subjects are separated well. (C) shows 
classification table using Naïve Bayes classification algorithm using leave one out 
methodology yielding 97% sensitivity.   
 
Figure A.1: Immunosignaturing of high/low IA-2 titer of T1D subjects 
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B. MAPPING RANDOM PEPTIDES IN TYPE 2 DIABETES TO GADA 
PROTEIN 
We selected 170 peptides that were significantly different in type 2 
diabetes immunosignature compared to controls. We mapped these 170 peptides 
against a suspected autoantigen in T2D pathway and found 6 peptides that 
aligned. Figure B.1 (A) shows random peptide sequence along with false 
discovery rate corresponding to the mapping process. (B) shows the GUITOPE 
analysis for 1000 iterations which indicated 1 predicted epitope.   
 
Figure B.1: GUITOPE analysis of T2D random peptides on GADA 
autoantigen 
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C. PEPTIDES LIST FOR VALIDATING PEPTIDES IN DECIPHER OF TYPE 
1 DIABETES IMMUNOSIGNATURE 
We ordered 20 peptides that were mapped on autoantigens of T1D. Table 
C.1 shows the peptide id. Ups indicate peptide that we predicted to be show 
higher binding. Down indicates peptides we predicted to be of less binding. 
Controls indicate peptides selected randomly on the part of the autoantigen.  
Table C.1: Peptide list for decipher of T1D 
Peptide Name Ordered Peptides Length 
IA-2 Ups LMSQGLSWHDDLTQYVIGSC 20 
IA-2 Ups DLTQYVISQEMERIPRLGSC 20 
IA-2 Ups RLPEPGGSSRAGDSSEGGSC 20 
IA-2 Ups EGTPASTRPLLDFRRKVGSC 20 
IA-2 Ups STRPLLDFRRKVNKCYRGSC 20 
IA-2 Controls MRLPGRPGGPGGSGGLRGSC 20 
IA-2 Controls VLLCLLLLGSRPGGCNAGSC 20 
Insulin Up YTPKTRREAEDLQVGQVGSC 20 
Insulin Up QCCTSICSLYQLENYCNGSC 20 
Insulin Down MALWMRLLPLLALLALWGSC 20 
Insulin Down SLQPLALEGSLQKRGIVEGSC 21 
Insulin Control DPAAAFVNQHLCGSHLVGSC 20 
GAD Up MWRAKGTTGFEAHVDKCGSC 20 
GAD Up EYLYNIIKNREGYEMVFGSC 20 
 203 
GAD down MSRKHKWKLSGVERANSGSC 20 
GAD down ANSVTWNPHKMMGVPLQGSC 20 
GAD down RHVDVFKLWLMWRAKGTGSC 20 
GAD controls ISNMYAMMIARFKMFPEGSC 20 
GAD controls VKEKGMAALPRLIAFTSGSC 20 
GAD controls IGTDSVILIKCDERGKMGSC 20 
 
 
D. PATTERNS IN STANDARD NORMAL SIGNATURE 
We ran more than 200 healthy samples on CIM 10k V.1 over the period of 
5 years. We then analyzed all the normal individual immunosignature in terms of 
how each peptide reacts in the healthy normal population. I termed this as 
Standard Normal Signature (SNS). We then found some interesting patterns 
among 10k peptides among the healthy individuals. While more than 80% of the 
peptides followed the normal distribution, there were some peptides which 
followed bimodal and other interesting distributions.  Figure D.1 shows the 
distribution of 10k peptides in Standard Normal Signature. We then asked how 
many peptides among the 10,000 are saturated in terms of their intensities. We 
observed that there were 12 peptides that had normalized intensity >1.75 in 95% 
of the healthy individual immunosignature (Standard Normal Signature). Table 
D.1 shows 12 peptides list from CIM 10k V.1 which were saturated in SNS.  
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Figure D.1: Patterns in Standard Normal Signature 
Table D.1: 12 peptides having intensities >1.75 in SNS 
KRKFQRQHSPVRPEFFTGSC  
AGAFRERRYKPMMWLHVGSC  
PVKYWAKSRVHTRGSWFGSC  
YMHRHFEGRGAPMNFRHGSC  
RFLRRKPWSMEAHAAQPGSC  
KEWQQRKARRYWHQWQDGSC  
YRRGWIGMIQRHRIKYEGSC  
VKGKLSNVPSWFNHFHSGSC  
ARYWWANVDIIIKGGMRGSC  
RWRSKYNPRPQYSNEYYGSC  
TRMYILHKRWQEAHNVNGSC  
VTGVKRPPLYNWTHGNVGSC  
 
